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Introduction 
Cardiovascular disease 
Cardiovascular disease is a leading cause of morbidity and mortality throughout the 
world.1 According to the World Health Organisation, 17 million deaths per year can be 
attributed to cardiovascular disease. This number is expected to rise with the shift in 
demographics to an aging population in the Western world2 and an increase in traditional 
risk factors (smoking, hypertension, diabetes, dyslipidemia) in the developing World.1 In 
addition to great human suffering, cardiovascular disease is responsible for substantial 
economical strain with costs for 2008 alone calculated to $448 Bn in the US and €192 Bn 
in the EU.3   
 
Two principal contributors to mortality in cardiovascular disease are coronary artery 
disease and heart failure (HF).1,2,4 Coronary artery disease starts with deposition of lipid 
particles in the wall of epicardial arteries, which over time progresses to an atherosclerotic 
plaque (Figure 1).5,6  
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Figure 1. Coronary artery disease represents a continuum from early deposition of lipids 
in the vessel wall (fatty streak) to the unstable plaque that can rupture and cause a total or 
subtotal obliteration of the vessel lumen. The latter situation is now classified as an acute 
coronary syndrome (previously denoted unstable angina pectoris). In stable coronary 
artery disease, progressive narrowing of the lumen diameter and endothelial dysfunction 
will result in a mismatch between myocardial oxygen supply and demand that can be 
experienced by the patient as chest pain (angina pectoris). From Abrams5 and reproduced 
by permission from Massachusetts Medical Society. Copyright Massachusetts Medical 
Society.
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The ratio of fibrosis to lipids determines the stability of the plaque with lipid rich plaques 
being considered the more unstable lesion.5,6 The reduction in blood flow of the artery, a 
consequence of reduced lumen diameter and endothelial dysfunction, results in a 
mismatch between myocardial oxygen supply and demand.5 In the classical case, this 
mismatch is experienced by the patient as chest pain in situations of high myocardial 
oxygen consumption (angina pectoris).5 Use of nitroglycerin rapidly normalizes the blood 
supply by dilating arterial and venous blood vessels, and sublingual nitroglycerin 
represents an efficient drug for symptomatic relief in patients with angina pectoris.5 
Patients with stable coronary artery disease should also receive treatment with platelet 
aggregation inhibitors, HMG-CoA reductase inhibitors (statins), and -blockers to prevent 
or delay disease progression.5
  
Patients with chest pain and unstable plaques require urgent therapeutic intervention to 
prevent a total occlusion of the epicardial artery.7 A model for the unstable plaque relates 
to the integrity of the luminal cap of the atherosclerotic lesion (Figure 1).5-7 In this model, 
unstable plaques are characterized by local inflammation, degradation by matrix 
metalloproteases,6 and neovascularization and intraplaque hemorrhages8 that will 
destabilize the cap and subsequently result in plaque rupture.5-8 In the situation of a plaque 
rupture, molecules in the core of the atherosclerotic plaque will be exposed, platelets will 
aggregate over the ruptured plaque, and the fibrinogen system will be activated to produce 
a fibrin clot tethering the platelets to the lesion.6,7 The triad of plaque rupture, platelet 
deposition, and fibrin clot will result in total or subtotal obliteration of the vessel lumen 
and this can happen within seconds (Figure 1). In this setting, which is referred to as an 
acute coronary syndrome (ACS),7 nitroglycerin will not alleviate symptoms. If the ACS 
results in cardiomyocyte cell death, as detected by elevated levels of and a rise-and/or-fall 
pattern in circulating levels of the cardiac specific troponins, the patient is diagnosed with 
an acute myocardial infarction (AMI).7,9 Patients with ACS but no dynamic elevations of 
troponin levels are diagnosed with unstable angina pectoris.7,9  
 
In 2006, coronary artery disease was responsible for approximately 1 out of every 6 US 
deaths.10 Improvement in the management of AMI to restore flow in the culprit lesion has 
reduced the short-term mortality,11 but late AMI related mortality is still high, often as a 
consequence of progressive myocardial remodeling.4 The changes in myocardial structure 
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after AMI include alterations in both cardiomyocytes and the extracellular matrix,12,13 
which are beneficial in the acute and subacute phase to preserve cardiac output and 
prevent myocardial rupture. However, in a subgroup of patients these compensatory 
processes will induce progressive loss of left ventricular (LV) function, and eventually the 
patient will develop overt HF (Figure 2).4  
 
 
 
Figure 2. Post-infarction heart failure is a progressive process that starts with the initial 
infarct, which over days may put a large part of the left ventricle at risk. Within days to 
months of a large myocardial infarct, global remodeling will induce and this may result in 
overall ventricular dilatation and decreased systolic function. Local changes in wall 
pressure and cardiomyocyte stretch together with paracrine and endocrine factors will 
affect the myocardial cells of both infarcted and non-infarcted myocardial tissue. From 
Jessup and Brozena4 and reproduced by permission from Massachusetts Medical Society. 
Copyright Massachusetts Medical Society. 
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As a consequence of improved treatment of ACS patients the prevalence of elderly 
subjects with antecedent AMIs will increase in the future.2,14 The increase in the number 
of subjects at risk of HF, both patients with prior AMI and elderly subjects with other risk 
factors for HF15 will increase the prevalence of HF in the next decade and make HF a key 
challenge for the cardiovascular community in the 21st century.  
The syndrome of heart failure 
HF is a syndrome that is categorized into different axes according to etiology, severity, 
phenotype, and structural pathology.4 A classical definition of HF is the inability of the 
heart at normal diastolic pressures or volumes to pump sufficient blood to the peripheral 
organs,16,17 which results in a shortage of oxygen and nutrients required for metabolism 
during rest or activity. Recently, a more clinically oriented definition has been proposed 
based on the combination of (1) typical HF symptoms (dyspnea, fatigue, ankle edema, 
etc), (2) typical signs of HF (tachycardia, tachyopnea, pulmonary rales, raised jugular 
venous pressure, evidence of elevated systemic pressure) and (3) objective evidence of 
structural or functional abnormality (mainly by echocardiography and raised natriuretic 
peptide levels, but also cardiomegaly, third heart sound, and cardiac murmurs).18 There 
are several conditions, besides AMI, which can result in HF (Table).  
Table. Common causes of heart failure 
Coronary artery disease/myocardial infarction 
Arterial hypertension 
Cardiomyopathies 
Valvular heart disease 
Cardiotoxins/drugs 
Congenital heart disease 
Tachyarrhythmias  
Endocrine diseases: Hypo/hyperthyroidism, pheochromocytoma, etc
Infiltrative diseases: Sarcoidosis, amyloidosis, etc 
Infections diseases: Chagas disease, HIV, etc 
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Establishing the underlying pathology in HF is essential as the etiology will influence 
therapeutic decisions;18 e.g. invasive therapy for patients with ischemic etiology, valvular 
surgery in patients with aortic stenosis, and septal reduction therapy  in patients with 
hypertrophic obstructive cardiomyopathy. The severity of HF also influences the treatment 
strategy, especially if the intervention is associated with substantial morbidity and 
mortality (e.g. valvular surgery). Severity of HF is generally classified according to the 
New York Heart Association (NYHA) functional class system and there is a close 
association between NYHA class and long-term prognosis.19 Some therapeutic 
interventions, e.g. aldosterone blockade and cardiac resynchronization therapy, are 
currently also only warranted in patients with class III and IV HF.18  
 
A third strategy to classify patients with HF, which transcends etiology of HF and disease 
severity, is to stratify patients according to the left ventricular ejection fraction (LVEF).4,20 
In this system, a cutoff of LVEF=50% divides the patients in two groups: (1) HF with 
preserved ejection fraction (HFPEF; LVEF50%) and (2) HF with systolic dysfunction 
(LVEF<50%). The principal pathology in patients with HFPEF is impaired relaxation of 
the myocardium,21 which leads to inadequate diastolic filling and increased pulmonary 
and systemic venous pressure (backward failure). In patients with systolic dysfunction, the 
principal pathology is poorly contracting ventricles resulting in low cardiac output 
(forward failure),22 but this may also result in backward failure and elevated pulmonary 
artery pressure. Hypertension, hypertrophic cardiomyopathy, and aortic valvular stenosis 
are important etiologies in patients with HFPEF, while systolic dysfunction often is a 
consequence of antecedent AMI or dilated cardiomyopathy. Of note, some patients with 
HFPEF can progress to systolic HF and ventricular dilatation with progression of the 
disease, e.g. in patients with aortic valvular stenosis.  
 
More recently, a fourth strategy to characterize HF has been proposed.4 This model 
focuses on the structural alterations of the myocardium and incorporates the progressive 
nature of HF. The patients are classified in four stages of HF with stage 1 representing the 
patient at risk of HF (hypertension, diabetes mellitus, etc), stage 2 representing subclinical 
HF, e.g. structural alterations in the heart but no symptoms, stage 3 overt HF, and stage 4 
is end-stage HF requiring transplantation or left ventricular assistant device for survival. 
This classification provides a conceptual model for studies of HF development, and 
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emphasizes the need to understand and identify the processes that drive the transition of 
HF from the patient at risk (stage 1) to the patient in end-stage HF (stage 4). Enhanced 
knowledge of the key processes in HF progression may improve patient care by 
identifying new tools for patient management and novel targets for therapeutic 
intervention.    
 
Basic pathology of heart failure 
Progressive loss of myocardial function in HF induces several compensatory mechanisms, 
both in the myocardium and in extra-cardiac organs.4,12 Although the etiology of HF 
influences therapeutic decisions, some pathophysiologic features are considered universal 
to all HF patients. Principal alterations in the failing myocardium are (1) cardiomyocyte 
hypertrophy, (2) altered gene expression in myocardial cells, (3) changes in the 
extracellular matrix composition, (4) alterations in membrane receptors and intracellular 
signaling, (5) dysfunctional calcium (Ca2+) homeostasis, and (6) enhanced cardiomyocyte 
apoptosis (Figure 3).16,23,24  
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Figure 3. Key alterations in the myocardium during heart failure development. A single 
cardiomyocyte is presented together with extracellular matrix. Biomechanical stress and 
paracrine and endocrine factors will induce alterations in cardiomyocyte membrane 
receptors and intracellular signaling, modulate calcium handling, and influence gene 
expression, including initiate hypertrophic gene expression (fetal gene expression). 
Fibroblast function and the extracellular matrix are also affected in the failing ventricle. 
From Hill and Olson23 and reproduced by permission from Massachusetts Medical 
Society. Copyright Massachusetts Medical Society. 
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These alterations in the failing myocardium seem to be preserved throughout evolution 
and can also be identified in non-mammalians.25  
 
There are also systemic alterations, most prominently increased circulating levels of 
cathecholamines26 and the ligands of the renin-angiotensin-aldosterone axis (RAAS)27 that 
are universal in HF.4 Increased neuroendocrine activity is beneficial for short-term 
survival by maintaining blood pressure, but this comes at the cost of impaired long-term 
prognosis.4,12,16,27,28 A prolonged elevation of catecholamine levels and RAAS activity 
will augment cardiomyocyte oxygen consumption, enhance myocardial fibrosis and 
hypertrophy, and increase the susceptibility for ventricular arrhythmias by altering 
intracellular Ca2+ handling.12,16 The importance of catecholamines and the RAAS axis in 
HF is reflected in contemporary HF therapy where -adrenergic blockers, angiotensin 
converting enzyme inhibitors, and angiotensin II receptor blockers all have been shown to 
reduce HF morbidity and mortality.18 However, in spite of progress in the treatment of HF, 
this syndrome still carries a poor prognosis with a dismal 30% five year survival rate 
recently reported from the Framingham cohort.29 Moreover, no therapy has so far been 
proven to efficiently reduce mortality in patients with HF and LVEF>50%.30 Hence, there 
is a clear need for better management strategies and therapeutic options in HF. Such novel 
strategies should explore systemic factors, as well as local alterations in protein synthesis 
in HF. By providing information on the pathophysiology of HF, these proteins could be of 
help to guide patient management and possibly also represent novel targets for therapy.  
Biomarkers in cardiovascular disease 
Diagnosing patients with ACS can be difficult as chest pain is frequent also in non-cardiac 
conditions such as thoracic myalgias, pulmonary embolism, thoracic abdominal aortic 
disease, and pleural effusion.31 Likewise, dyspnea, a cardinal symptom of HF, frequently 
indicates non-cardiac disease, including asthma and chronic obstructive pulmonary 
disease, pneumonia, and pulmonary embolism.32 A late diagnosis of ACS and HF will 
delay the start of appropriate therapy, and tools that can help improve diagnostic accuracy 
are therefore of clinical interest.   
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Biomarkers are defined as a characteristic that is objectively measured and evaluated as an 
indicator of (normal) physiology, pathophysiology, or as a pharmacological response to 
therapy.33 A recording (ECG, Holter, etc) or an imaging test (echocardiogram or CT scan) 
may be referred to as a biomarker, but the term biomarker is most commonly used in 
association with measurements of substances in bodily fluids, and especially substances in 
peripheral blood.34 Biomarkers are used for diagnosis in several aspects of clinical 
medicine, including screening for prostate cancer (prostate specific antigen)35 and to 
diagnose pregnancy (human chorionic gonadotropin).36 In the last decades, biomarkers 
have entered the field of cardiology with great force, although the concept of using 
circulating markers to diagnose cardiac disease is not new.37 Prototypical cardiac 
biomarkers are (1) the cardiac specific troponins I and T (cTnI, cTnT) and (2) peptides 
derived from pro-B-type natriuretic peptide (proBNP1-108 [subscript indicative of amino 
acid position]), which are referred to as aminoterminal (NT)-proBNP1-76 and BNP1-32 (e.g. 
proBNP77-108).38 Troponins and the BNPs complement each other as troponins is 
considered to reflect cardiomyocyte necrosis,39 while proBNP secretion increases by 
cardiomyocyte stress such as stretch, hypoxia, and inflammation (Figure 4).40-42   
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Figure 4. A large number of substances have been proposed as cardiovascular biomarkers. 
The figure depicts some established and novel biomarkers according to possible 
pathophysiology reflected by the biomarker, although for the majority of biomarkers this 
has not been firmly established. The illustration demonstrating an unstable plaque in the 
left anterior descending artery, myocardial necrosis, and impaired left ventricular function 
is courtesy of Ole-Jacob Berge, MD.   
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Of note, the secretion of proBNP is part of the neuroendocrine activation in HF, but 
represents a counteractive protective mechanism counteracting the effects of the 
adrenergic system and the RAAS axis.42  
 
The organ specificity of troponins and the BNPs makes these ligands excellent biomarkers 
for identifying cardiac disease with superior sensitivity and specificity to other diagnostic 
tools.7,9,18,39 This is also reflected in the current definition of AMI, which is based on a 
characteristic rise and fall pattern in troponin concentration.9 Similarly, measurements of 
BNPs have been shown to complement and improve physician assessment of HF in 
patients with dyspnea.32,43 The role of BNPs as diagnostic HF biomarkers is recognized in 
updated guidelines and elevated levels of the BNPs are included as key factors to identify 
structural and functional evidence of HF in the most recent guidelines from the European 
Society of Cardiology.18 In addition to diagnostic utility, biomarkers are useful for risk 
stratification, to guide and monitor therapy, and to identify the pathophysiology in the 
individual patient (phenotype characterization, Figure 5).44  
 
 
 
Figure 5. Areas in which cardiovascular biomarkers could help improve patient care. 
From Morrow and de Lemos44 and reproduced by permission from Wolters Kluwer 
Health. 
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For prognosis, both the troponins and BNPs represent strong biomarkers across the 
spectrum of cardiovascular disease.45-53 Recently, troponins and natriuretic peptides have 
also been reported to provide prognostic information in non-cardiac conditions with 
compromised myocardial function.54,55 Hence, regardless of the condition, there seems to 
be a proportional increase in mortality and adverse events with higher levels of troponins 
and BNPs. Moreover, the information obtained by measuring troponins and BNPs 
provides incremental information to established risk indices as examined by several 
statistical methods. A number of other proteins have also been proposed as novel 
cardiovascular biomarkers (Figure 4),38 but currently only a minority of these markers has 
shown real clinical potential and there is a need for further testing before they can be 
considered for clinical use.56  
 
The potential of biomarkers to guide patient management is reflected in the current 
strategy for non-ST elevation ACS patients.7 As mortality and adverse events are more 
common in patients with non-ST elevation AMI (positive troponin profile, NSTEMI) than 
in patients with normal troponin profile (unstable angina pectoris),45 patients with 
NSTEMI are prioritized for angiography over patients with unstable angina pectoris.7 
Similarly, several studies have recently assessed the effect of using BNPs to guide therapy 
in ambulatory patients with HF.57-65 The rationale for BNP guided therapy is to identify 
non-responders and to prevent disease progression at an early stage before the patient 
develops decompensated HF.66,67 Although appealing based on the current understanding 
of proBNP secretion, not all studies with therapy guided by the BNPs have shown 
superiority over the standard strategy of titrating medication according to guidelines and 
symptoms.59,60,62-64 One explanation for the divergent results could be heterogeneity of the 
patients enrolled in the studies and that several different target of the BNPs have been 
implemented.66,67 Furthermore, there seems to be increasing recognition that patients <75 
years with systolic HF benefit from BNP guided therapy,68,69 although also elderly patients 
profited from NT-proBNP guided therapy in the PROTECT study,65 which is considered 
the premium biomarker-guided study so far.67   
 
There is increasing recognition among researchers conducting biomarker studies that the 
field needs to advance from descriptive studies on prognosis to studies that provide more 
pathophysiological understanding.67,70 By focusing more on biomarkers that can assist in 
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subgrouping patients according to pathophysiology; e.g. adrenergic tone, inflammatory 
status, extracellular matrix turnover, etc., biomarkers may be useful for identifying patient 
phenotype.70 This could also help improve our understanding of the complex 
pathophysiology of HF. To date, a large number of cardiovascular biomarkers have been 
reported to improve risk assessment;38 however, few studies have used this information to 
characterize patient phenotype or to guide therapy.  
 
One groundbreaking study that used biomarker levels to include patients was the 
Scandinavian Simvastatin Survival Study (4S).71 In 4S, patients with coronary artery 
disease and total cholesterol levels of 5.5-8.0 mmol/L were randomized to statin therapy 
or placebo, and there was a consistent reduction in mortality and cardiovascular events in 
patients on simvastatin. Since then, statin therapy has proved to be beneficial in patients 
with coronary artery disease in general,7 but the principle of using lipid levels to identify 
high-risk patients who will benefit from statin therapy was introduced with 4S. This 
principle currently forms the basis of recommendations on the use of statins in the general 
population.72  
 
The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating 
Rosuvastatin (JUPITER) is another statin study which used biomarkers to guide therapy.73 
In JUPITER, apparently healthy individuals with an acceptable lipid profile, but C-
reactive protein (CRP) levels >2.0 mg/L, were randomized to either rosuvastatin or 
placebo. Analogous to 4S, statin therapy also reduced the risk of the combined primary 
cardiovascular endpoint in JUPITER, although the numbers needed to treat obviously was 
much higher in this low risk cohort than in 4S. It is still debated whether the results of 
JUPITER should be implemented in clinical medicine,74 but regardless of that, JUPITER 
was an interesting study by demonstrating that targeting an intervention according to a 
biomarker cutoff could be successful in a low risk population.   
 
Except for these two statin success stories, limited information is currently available to 
recommend changes in patient treatment according to biomarker levels. This is also true 
for the established cardiovascular biomarkers troponins and the BNPs in the non-acute 
setting, e.g. in patients with subclinical cardiovascular disease or in stable HF. One key 
factor, which has prevented the use of prognostic biomarkers for guidance of therapy, is 
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the lack of information on the pathophysiology reflected by most biomarkers. Hopefully, 
by understanding more of this pathophysiology, physicians will be able to stratify patients 
according to phenotype and have a rationale for initiating specific therapy in the individual 
patient (personalized therapy).70 This strategy contrasts with current guidelines for patients 
with ACS and HF which recommend that the same therapy should be applied to all 
patients.7,18 Still, to utilize the true potential of personalized therapy in ACS and HF, new 
and established biomarkers should be combined to cover the network of pathophysiology 
in these complex conditions.  The need for additional cardiovascular biomarkers has 
spurred a search for new cardiovascular biomarkers and several proteins have been 
proposed as candidates (Figure 4).38,75 However, to demonstrate clinical potential these 
biomarkers should fulfill a set of standardized criteria (Figure 6).44  
 
 
Figure 6. Benchmarks for novel cardiovascular biomarkers. From Morrow and de 
Lemos44 and reproduced by permission from Wolters Kluwer Health. 
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According to these benchmarks, the marker should be (1) stable and easy to use, (2) 
associated with the outcome of interest in several independent cohorts, (3) provide 
incremental information to standard clinical assessment, and (4) help the physician to treat 
the patient better.44 The current statistical methods advocated to explore these new 
biomarkers are multivariable models to assess incremental information, receiver operating 
analysis to explore accuracy, and reclassification scores (net reclassification index and 
integrated discrimination index) to assess calibration of established risk models.76,77  
 
A strategy, which seems intriguing but currently lacks sufficient scientific merit, is the use 
of several markers in a panel (multimarker approach) to provide a comprehensive 
characterization of the phenotype of the individual patient.78 The success of the 
multimarker strategy will depend on the identification of strong new biomarkers, which 
can complement the information from the established markers troponins and the BNPs.   
Production of granin proteins   
The chromogranin-secretogranin (granin) proteins are a family of proteins characterized 
by a high proportion of acidic amino acids and several dibasic cleavage sites.79 Post-
translational processing of the granin proteins at cleavage sites produces multiple short 
~30 amino acid peptides.79-82 This extensive processing of the precursor prohormone is a 
hallmark of the granin protein family.79 Proconvertase (PC) 1/3 and PC2 constitute the 
most important proteases involved in the processing of the granin proteins,83,84 although 
plasmin has also been identified as an enzyme which can cleave chromogranin (Cg) A.85  
The granin proteins have several characteristics in common with other prohormones, such 
as proopiomelanocortin and proenkephalin, but can be differentiated from the other 
prohormones by the large size of the granin proteins, which is >400 amino acids for CgA, 
CgB, and secretogranin (Sg) II.79 The calculated molecular mass of CgA, CgB, and SgII 
are 50 kDa, while the largest classical neuropeptide prohormones have a size of 
approximately 30 kDa (proopiomelanocortin and proenkephalin of ~265 amino acids).79 
Furthermore, most other prohormones are only processed at one cleavage site producing 
two shorter fragments, while 9-16 cleavage sites have been reported for CgA, CgB and 
SgII.79 The high number of cleavage sites result in complex processing of the 
prohormones with multiple shorter granin peptides79,80 and this was identified already 
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from the early studies on granin processing.86-88 The processing of granin proteins is also 
less stringent compared to other prohormones,79 which results in partially processed 
truncated peptide fragments together with some fully processed peptides. The complexity 
of granin processing makes the characterization of the short peptides more complicated 
than for most other prohormones.79 Still, heterogeneity of processed proteins is not unique 
to the granin proteins and this has also been demonstrated for proBNP1-108 processing89 
with a substantial proportion of circulating BNP1-32 being truncated fragments.90 
 
The index member of the granins, CgA, is a 439 amino protein (Figure 7) which was first 
demonstrated in the adrenal medulla,91 but later has been identified throughout the 
neuroendocrine system.92
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Figure 7. Overview of the principal granin proteins chromogranin (Cg) A and B and 
secretogranin (Sg) II. Shorter fragments of the granin proteins are also presented together 
with the proposed role of these peptides in pathophysiology and as disease biomarkers 
(not including data from paper #4 of this thesis). Vasostatin II is presented as VST II1-115 
and catestin as CST352-372 under CgA, while secretoneurin is presented as SN154-184 under 
SgII. From Bartolomucci et al79 and reproduced by permission from the Endocrine 
Society. Copyright 2011, The Endocrine Society.  
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The synthesis of CgA in the neuroendocrine system, and the increased production in 
malignant cells,93 has made circulating CgA a clinical useful marker of neuroendocrine 
tumors (pheochromocytomas, carcinoids, etc.).94 Moreover, circulating levels of CgA are 
closely correlated with catecholamine levels in situations of enhanced adrenergic tone,95-97 
hence promoting a role for CgA as an index of neuroendocrine activity during stress.98 
This could be of clinical value as technical requirements for catecholamine analysis 
renders epinephrine and norepinephrine measurements impractical for routine use, while 
CgA seems to be a stable protein with a high signal-to-noise ratio99 that can be analyzed in 
a general clinical laboratory.100 Still, it should be acknowledged that circulating CgA 
levels are not a perfect surrogate marker for adrenergic tone as CgA is also produced in 
non-neuroendocrine cells.101-106 Moreover, the production in non-neuroendocrine organs 
seems to increase with pathology,105-109 which suggests that these organs could make a 
more pronounced contribution to circulating levels during disease than in the steady-state 
situation. This could be relevant for cardiovascular disease as cardiomyocytes increase 
their CgA synthesis in HF.109  
 
CgB and SgII are the two other principal granin proteins. CgB is a 657 amino acid protein 
with an N-terminal loop due to a disulfide bridge which is also present in CgA (Figure 
7).79 This characteristic 3-D structure forms the basis for the classification of these 
proteins as chromogranins, while SgII is a 587 amino acid protein with a linear 
aminoterminal end (Figure 7).79  
 
CgB and SgII are also produced throughout the neuroendocrine system,88 (chromogranin 
B is denoted as secretogranin I in this paper) but the expression of the granin proteins is 
not uniform across organs110,111 with high chromogranin concentration in the adrenal 
medulla,86,112 while SgII production is prominent in the pituitary gland.112,113 Analogous to 
the results for CgA, there are also organs outside of the neuroendocrine system that 
produce CgB and SgII.102,108 The ratio between production in the neuroendocrine system 
and non-neuroendocrine organs has not established for these granins and may also be 
different for CgB and SgII. 
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Regardless of the localization, a common denominator for cells that produce granins 
seems to be a high secretory rate.86-88,92-94,101-103,107-113 In contrast to the previous outdated 
model of granin production in the neuroendocrine system,80,81 the literature now suggests 
that all cells with marked exocytosis will have granin production. This new model for 
chromogranin A production is supported by enhanced synthesis of granin proteins in cells 
that are transformed to a secretory phenotype during later stages of disease. Prominent 
examples of such cells are tumor cells, e.g. in small cell lung cancers104,105 and in prostate 
cancers,108,114 and cardiomyocytes during HF development.109 Whether this model was 
relevant also for CgB and SgII production was not established prior to the work described 
herein. 
 
Physiological role of granin proteins 
The model of granin production in cells with marked exocytosis is supported by the 
importance of the granin proteins for granulogenesis.115-119 Granin proteins stabilize 
intracellular granula by binding Ca2+ and proteins, and the granin proteins are key 
elements in the nucleus of secretory vesicles destined for regulated secretion (Figure 8).120  
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Figure 8. The granin proteins are crucial for granulogenesis. The granin proteins stabilize 
granula by binding to lipid-raft sorting receptors and by forming a dense core substrate 
with calcium and prohormones and peptides destined for regulated exocytosis. From Kim 
et al120 and reproduced by permission from the American Physiological Society.   
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The prominence of granin proteins for granulogenesis has been convincingly shown in
vitro and in vivo, including in mouse CgA and CgB knock-out (CgA-/- and CgB-/-) 
models.121-123 In the CgA-/- mice, catecholamine levels were elevated due to impaired 
granulogenesis and depletion of secretory vesicles in the adrenal medulla.121 Of note, these 
alterations were obliterated after transfecting the CgA-/-  mice with the human variant of 
the CgA gene. Analogous, CgB-/- mice demonstrated alterations in the release of insulin, 
glucagon and somatostatin from the pancreas.123 The effect of CgB for granulogenesis has 
also been demonstrated in vitro by overexpressing CgB in non-neuroendocrine cells.124 
The role of SgII in granulogenesis has not been established, but we postulate that also SgII 
will influence granula stability as this protein co-localize with the chromogranins and 
binds Ca2+ with superior affinity to CgA.125   
 
The ability of granin proteins to bind Ca2+ could also be important for intracellular 
processes besides granulogenesis.126 Granin proteins interact with the luminal side of the 
inositol 1,4,5-triphosphate receptor (IP3R),127,128 a receptor of increasing importance in 
cardiac disease,129 and enhance the Ca2+ efflux through the receptor complex.125,126,128,130-
132 Among the granins, CgB has superior affinity for Ca2+ binding and also provides the 
strongest influence on IP3R activity.128 The combination of high-capacity, low-affinity 
Ca2+  binding and a positive effect on receptor activity126 indicate a role for granin proteins 
in cardiomyocyte Ca2+ homeostasis. Of note, this model was recently supported for CgB in 
the myocardium where CgB was an intermediate in angiotensin II-induced Ca2+ signaling 
and cardiomyocyte hypertrophy.133 Whether CgB may modulate cardiomyocyte Ca2+ 
channels besides the IP3R has not been examined, and currently no information is 
available on the association between CgA and SgII and Ca2+ channels in the myocardium.  
 
The extracellular properties of the granin proteins are attributed to the effects of the 
multiple short ~30 amino acids peptide fragments.79,80 However, despite the high rate of 
processing and the high number of fragments, only a minority of these peptides have been 
found to influence cellular function. Extrapolating from experimental animal models, the 
two CgA fragments vasostatin II (CgA1-113) and catestatin (CgA344-364) seem especially 
important for cardiovascular pathophysiology.134 A peptide from SgII, secretoneurin 
(SgII154-186), could also have functional properties of relevance for cardiovascular 
disease.135,136 However, prior to this work, no study had assessed the functional relevance 
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of SgII in cardiovascular disease. In addition, other granin fragments have been identified, 
including pancreastatin (CgA240-288) that influences glucose metabolism and CgB 
fragments of the innate immune system,79,80 but currently these peptides have not been 
assigned a role in ACS or HF. 
 
The CgA fragment vasostatin II influences cardiovascular physiology by directly 
promoting peripheral vasodilatation137 and by counteracting -adrenergic stimulation of 
contractility109,138 and excessive -adrenergic and endothelin-1 signaling in 
cardiomyocytes.139 Vasostatin II has also been found to prevent tumor necrosis factor- 
enhancement in endothelial cell permeability140 by modulating the endothelial 
cytoskeleton,141 which could be important in HF to reduce symptoms of congestion and to 
improve prognosis. A negative inotropic effect has also been demonstrated for 
catestatin.142 Moreover, as catestatin reduces secretion of catecholamines from the adrenal 
medulla143 and modulates -adrenergic signaling in cardiomyocytes,144 catestatin could 
represent an important counteractive mechanism to excessive adrenergic drive in patients 
with cardiovascular disease.145,146 Catestatin has also been demonstrated to protect from 
myocardial ischemia-reperfusion injury in the Langendorff model147 and to induce 
angiogenesis in vitro and in vivo.148  
 
The protection by CgA and catestatin to catecholamines could be of relevance for essential 
hypertension as studies have found specific genetic alterations linked to CgA149,150 and 
catestatin synthesis151 associated with elevated blood pressure. The promoter region of 
CgA controls the gene expression by mediating responsiveness to transcription factors and 
variants (polymorphism) in this region will influence CgA synthesis.152 In contrast, direct 
alterations in the CgA gene will influence the amino acid sequence of the protein and 
render the protein more susceptible for degradation or alter the potency of the protein by 
changing the 3-D structure.142 The association between CgA production and hypertension 
is supported by a twin-heritage linkage study in which the subjects at risk of hypertension 
had reduced circulating catestatin levels prior to developing hypertension.151  
 
A third peptide from the granin protein family which could play a role in cardiovascular 
pathophysiology is the 33 amino acid peptide secretoneurin.136 This peptide has been 
found to attenuate ischemia-reperfusion injury in skeletal muscle153 and the brain,154 but 
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an effect of secretoneurin on myocardial injury has not been examined. Secretoneurin also 
protects against apoptosis and potently induces angiogenesis155 and vasculogenesis,156 
processes that could be important for large groups of patients with cardiovascular disease.     
 
Conceptual model for granin proteins in cardiac disease   
The model of the heart as an endocrine organ was postulated by Braunwald in 1964 in 
relation to norepinephrine production in the myocardium.157 This model was advanced by 
de Bold and co-workers in 1989 with the discovery of atrial natriuretic peptide158 and by 
the group of Nakao and Imura in 1991 that identified proBNP1-108 as the principal hormone 
of the ventricles.159 Analogous to the phenotype of several malignancies, the 
cardiomyocytes attain a secretory phenotype with advanced stages of HF. The close 
association between myocardial function and secretion of proBNP1-108159 forms the basis 
for the sensitivity and specificity of BNP and NT-proBNP as cardiac biomarkers.42 The 
association between myocardial function and cardiomyocyte protein secretion also 
provides the rationale for examining other myocardium synthesized proteins as novel 
cardiovascular biomarkers.  
 
The model of the heart as an endocrine organ formed the basis for the first study on the 
granin proteins in cardiovascular pathophysiology.101 The investigators hypothesized that 
CgA and CgB would be co-localized with natriuretic peptides in the atrial granula, which 
was similar to the role of the chromogranins as the core substrate in secretory granula of 
neuroendocrine cells. Supporting their hypothesis, the authors were able to demonstrate 
CgA and CgB production in atrial cardiomyocytes and to show co-localization between 
atrial natriuretic peptide and chromogranins in granula.101 CgA was also found to be 
processed to shorter fragments in atrial tissue, while there was no post-translational CgB 
processing. A comparison between chromogranin production and processing in the healthy 
and the diseased myocardium was not performed. 
 
A different avenue of granin research in the early 1990s related to the association between 
circulating CgA and catecholamine levels. Enhanced activity in the neuroendocrine 
system and elevated levels of catecholamines are acknowledged risk factors in cardiac 
disease,28 but epinephrine and norepinephrine play a modest role as clinical biomarkers 
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due to the short half-life and large day-to-day and time-of-day variation of these 
hormones.98 Analysis of catecholamines are also time consuming and requires 
complicated analytical methods, most often high-performance liquid chromatography. In 
contrast, both CgA and CgB have been reported to be robust and stable proteins with a 
high signal-to-noise ratio.99,160 Accordingly, CgA was tested as a surrogate marker for 
catecholamines, and this association was validated in situations of marked neuroendocrine 
activity with correlation coefficients of 0.7-0.8.95-97 In contrast, there was only modest 
correlation at rest and CgA levels seem to represent a valuable index of neuroendocrine 
activity in situations of marked stress, but not in the steady-state situation.   
 
The importance of CgA for adrenal medulla function and catecholamine secretion was 
later also supported by studies performed by the group of O'Connor using the genetically 
modified CgA-/- mouse.121 The CgA knock-out mice showed marked depletion of granula 
in the adrenal medulla, but elevated circulating catecholamine levels. The higher levels of 
circulating catecholamines were attributed to defective storage of catecholamines in the 
adrenal medulla and subsequent constitutive catecholamine release. Moreover, these mice 
exhibited evidence of LV hypertrophy and impaired diastolic and systolic LV function, 
which were prevented by inserting the human variant of the CgA gene in the in CgA-/- 
mice. The myocardial remodeling in CgA-/- mice was also prevented by the infusion of the 
CgA fragment catestatin.121 
 
The merit of CgA as an index of neuroendocrine activity was cited by the group of Ferrari 
as the rationale for testing CgA as a cardiovascular biomarker.161 In a group of 160 
patients with chronic HF, Ceconi et al found CgA levels to be increased in proportion to 
HF severity as measured by the NYHA functional class. Moreover, CgA levels were 
strong predictors of mortality or the need for cardiac transplantation. The association 
between CgA levels and the endpoint of mortality or transplantation was also statistically 
significant in multivariable analysis, including a model that adjusted for LVEF, NYHA 
class, and BNP and norepinephrine levels. Omland and coworkers have later demonstrated 
prognostic utility of CgA measurements in two cohorts of patient with ST elevation 
myocardial infarction (STEMI).162,163 Of note, in the two latter studies there were no 
significant correlations between circulating CgA and catecholamine levels. This was 
surprising based on the literature and could indicate additional organs besides the 
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neuroendocrine system contributing to circulating CgA levels in cardiovascular disease.164 
However, there was heterogeneous blood sampling (range day 1-10) in the STEMI 
studies162,163 and the data should not be interpreted as evidence that the adrenal medulla 
does not contribute to circulating CgA levels in ACS or HF patients. Other studies of 
patients with more extreme sympathetic activation have demonstrated a close correlation 
between CgA and norepinephrine levels, including during cardiac arrest and resuscitation 
(r=0.84, p<0.001).96    
 
Finally, in the initial stages of this work, an Italian consortium reported increased 
production of CgA in the failing myocardium, including N-terminal CgA fragments.109 
This could be of importance as vasostatin II has been found to counteract -adrenergic 
inotropic effects in experimental models.134 Moreover, CgA was found to co-localize with 
proBNP1-108 in cardiomyocytes. The presence of N-terminal CgA fragments in the heart 
has later been verified by a proteomics approach in the healthy rat myocardium.165 
 
Another recently published paper found CgB to be a positive modulator of IP3R activity 
in cardiomyocytes in vitro and in vivo.133 In this work, CgB was also identified as an 
important intermediate in cardiomyocyte angiotensin II signaling by regulating IP3R-
mediated Ca2+ efflux from the sarcoplasmic reticulum. The results of this study support a 
model in which CgB, IP3R, and the transcription factor NF- regulate myocardial 
hypertrophy and influence proBNP1-108 production, thus linking CgB expression directly 
to the synthesis of BNP and NT-proBNP in the LV. This work also found CgB levels to be 
increased in the hypertrophic LV after angiotensin II infusion, but the investigators did not 
examine CgB production in HF models. Thus, although some information were available 
prior to the start of this project in 2006,164,166 there were several unanswered questions 
relating to the chromogranins in cardiovascular disease that we wanted to explore in this 
thesis. Moreover, no information was available on the role SgII plays in cardiovascular 
disease.   
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Aim of thesis 
The general aim of this thesis is to examine the role granin proteins play in cardiovascular 
disease  
 
Specific aims: 
1st  paper: To examine CgA as a prognostic biomarker across the spectrum of ACS, 
e.g. in patients with STEMI, NSTEMI, and unstable angina pectoris 
 
2nd paper:  To examine CgA as a prognostic biomarker in a large cohort of stable HF 
patients treated according to updated guidelines 
 
3rd paper: To examine CgB production and circulating levels in HF by experimental 
and clinical studies  
 
4th paper: To examine SgII levels in HF and effects of the SgII fragment secretoneurin 
on post-infarction HF development by a translational investigational 
program 
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Methodological considerations 
Clinical biomarker studies 
There are four different clinical cohorts included in this thesis: (1) 1268 patients from the 
Prognosis and Risk in Acute Coronary Syndromes in Sweden (PRACSIS) program 
included during mid-September 1995 to mid-March 2001 at Sahlgrenska University 
Hospital, Gothenburg, Sweden, (2) 1233 patients included from Aug 6 2002 to Feb 28 
2005 in the GISSI-HF trial of Italy and Switzerland, (3) 80 patients recruited during 2007 
at Akershus University Hospital, Lørenskog, Norway: 70 patients from the outpatient HF 
clinic and 10 patients hospitalized for acute HF, and (4) 58 ambulatory patients with stable 
HF (no hospitalization for acute HF <3 months prior to study commencement) from cohort 
#3.  
 
The first two cohorts are prespecified biomarker substudies of the large clinical studies 
PRACSIS167 and GISSI-HF.168 In the PRACSIS program, 2335 patients were included to 
study the epidemiology of ACS in Sweden. In the GISSI-HF trial, 6975 patients were 
included to assess the effect of add-on treatment with rosuvastatin169 and n-3 
polyunsaturated fatty acids170 to conventional therapy in stable HF. The selection of only a 
subgroup of the patients to the biomarker studies might reduce the external validity of the 
results. This may be partially correct for the PRACSIS biomarker study, in which a higher 
proportion of patients were diagnosed with AMI compared to the prevalence of AMI in 
the total PRACSIS cohort.171 For the GISSI-HF study, there were no differences in 
baseline characteristics between the patients in the GISSI-HF biomarker substudy and the 
rest of the GISSI-HF trial.172 The large sample size (>1000 patients) in papers #1 and #2 
support that our results are valid in  the majority of patients with ACS and stable HF.  
 
The two last cohorts were recruited from Akershus University Hospital, a teaching 
hospital situated in the greater Oslo region with a catchment area of 460000. In paper #3, 
we recruited 70 patients from the outpatient HF clinic while the last 10 patients were 
recruited among patients hospitalized for acute-on-chronic HF at Akershus University 
Hospital.173 For paper #4, only the patients with stable HF were included from cohort #3 
to obtain a more homogenous cohort.174 Stable HF was defined as no hospitalization for  
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acute HF during the last 3 months prior to study commencement. All of the clinical studies 
were conducted according to the Declaration of Helsinki, approved by the Regional Ethics 
Committees, and all participants signed an informed consent prior to study 
commencement.  
 
The clinical relevance of a biomarker is characterized by several features, but a core 
fundamental is the ability of the biomarker to improve established prognostic, diagnostic, 
or therapeutic strategies.44 Accordingly, to enable assessment of incremental information, 
diligent information on patient history, clinical examination, and the results of diagnostic 
and prognostic tests should be collected. The clinical cohorts of this thesis were all 
prospectively planned and all patients were subjected to an extensive clinical examination. 
All patients in cohorts #2-4 have measurements of BNPs and most patients also had an 
updated echocardiographic examination. In cohort #1, standard clinical and laboratory 
data from the hospital admission were available in all patients, while cTnT and proBNP 
measurements were only available in a subgroup of patients as these biomarkers were not 
part of the clinical routine in the first years of the PRACSIS study. A large proportion of 
the patients in PRACSIS have echocardiographic measurement of LVEF, which is a 
strength of the study. 
  
We assessed incremental information by CgA to established risk indices in papers #1 and 
#2 by multivariable logistic regression analysis. In the GISSI-HF substudy, we also 
calculated the C statistic of established risk factors and compared this to the C statistic of 
established risk factors combined with CgA measurements. Receiver operating 
characteristics analysis was not performed in paper #1.  
 
Experimental HF model
The use of experimental animal models has been instrumental in promoting cardiovascular 
research in the 20th century.175 The ability of the researcher to control all aspects of the 
experiment provides a unique model in which external confounders can be largely 
controlled for. In contrast, factors such as genetic make-up, age, gender, comorbidity, and 
medication will influence results in patients, thus reducing the ability to make definite 
assumptions of causality in clinical studies.  
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Until the late 1970s, basic cardiac research was performed in large animal models such as 
pig, dog or sheep.176 The strengths of these models are the size of the animal, which makes 
surgery more easy, and the possibility to perform serial blood sampling without 
compromising hemodynamic stability. However, as large animal models are expensive 
and require large animal facilities, these models have now largely been replaced by small 
animal models.175 The progress in microsurgery has permitted most experimental models 
originally developed in large animals to be transferred to mice and rats. This also relates to 
the post-AMI HF rodent model with a permanent ligation of the left main coronary artery, 
which was refined by Pfeffer and coworkers in the late 1970s.177 By using mice and rat the 
influence by genetic variation is also annihilated due to special breeding strategies, which 
produce animals with identical genetic make-up.178 The stringent control of 
microbiological contamination in rodent breeding facilities ensures that all animals are 
supplied in good health, which will reduce variation due to non-controlled external 
factors. Accordingly, the many advantages of mice and rats over larger animal models 
have changed experimental cardiac research during the last three decades. Of note, 
although obviously different by phenotype, examination of the mouse genome has 
demonstrated that 99% of mouse genes have a human homolog, which supports the 
validity of rodent models to explore human disease.179  
 
We have used the mouse strain C57-Black 6 (C57BL/6) for our in vivo work in paper #3 
and #4. The C57BL/6 strain has nearly identical genetic make-up due to several 
generations of inbreeding and is widely used in cardiovascular research. The animals were 
obtained in week 5 and acclimatized for one week in-house before surgery was performed 
in week 6. Only male mice were used to avoid influence by the cyclic variation of sex 
hormone. To reduce the effect of the anesthesia on cardiac function, animals were 
anesthetized with propofol and isoflurane, which have less cardiodepressive effects than 
other anesthetics. After being trachetomized, the mice were connected to an animal 
ventilator and ventilated with a mixture of 98% oxygen and 2% isoflurane throughout the 
surgery. Via a left-sided thoracotomy, pericardectomy was performed followed by ligation 
of the left main coronary artery in the HF group. After finishing surgery, all animals 
received 0.01 ml buprenorfin s.c. before being weaned from the ventilator.  
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As the surgery alone can induce changes to the animals, it is important to compare animals 
in the HF group to control animals that also have been subjected to anesthesia and surgical 
trauma. We obtained relevant control animals by performing sham surgery on animals that 
were also trachetomized, mechanically ventilated, and subjected to thoracotomy and 
pericardectomy but had no coronary artery ligation. By comparing granin levels in HF 
animals with sham animals, the increase in granin synthesis was not a result of surgery per
se, but rather supports our hypothesis of enhanced granin production in HF.  
 
Although widely used, some limitations to the post-infarction HF mouse model should be 
acknowledged. The most striking difference relates to the healthy endothelium of the 
coronary arteries in mice compared to the widespread atherosclerosis found in elderly 
patients with coronary artery disease and HF.5 However, as collateral circulation seems to 
protect in the setting of acute ischemia,180 this could actually represent a disadvantage for 
the animal model. Another difference is the use of young mice for our experiments while 
the median age for AMI is 67 years in men and 70 years in women.181 As aging influences 
myocardial structure and function,182-184 our model could overestimate the plasticity of the 
myocardium to recover after AMI. Still, our goal was not to assess morbidity and 
mortality after AMI, but rather to explore the hypothesis of enhanced granin production in 
the failing myocardium, and we believe our model is valid to answer this question.  
 
Strict echocardiographic criteria, which previously have been validated by invasive 
pressure measurements,185 were employed to make sure that only animals in 
decompensated systolic HF were included in the HF group. The presence of myocardial 
remodeling and congestion were confirmed by measuring LV mass and lung weight in all 
animals. Other groups have previously also demonstrated substantial alterations in gene 
expression one week after AMI in mice with HF,186 which indicates that our model 
recaptures key molecular alterations in patients with HF. Accordingly, the model and the 
time point we chose to study granin expression in HF should give us representative data 
which can be extrapolated to post-AMI HF development in patients.  
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All of the animal experiments were performed according to established guidelines and 
were approved by the Norwegian Animal Research Authority. 
 
Echocardiography
Echocardiography is the principal method to assess myocardial structure and function. The 
estimation of LVEF represents the most common index by which to quantify systolic 
function.187 In this thesis, we report LVEF in all patients with HF (papers #II-IV), 
although not all patients had a recent examination as they were deemed stable by the 
treating physician and thus not in need of a new echocardiography. LVEF was also 
calculated in the majority of patients in paper #I (990 of the 1268 patients, 78%), which is 
superior to the proportion of patients with LVEF measurements in other ACS biomarker 
studies.49,52,188-190  
 
Echocardiography was also used to identify the mice with systolic HF one week after 
AMI. The tachycardia of the mice and the short distance from the thoracic wall to the 
heart represent technical challenges for echocardiography,191 but this can be compensated 
for by proper equipment and an experienced investigator. For all our echocardiographic 
examinations in mice, we used a special small rodent transducer. This system produces 
high quality images and helped us differentiate between animals with HF and animals with 
minor infarcts and preserved systolic function. To only include animals that were in HF, 
we used echocardiographic criteria that are considered sensitive and specific for HF and 
which previously have been validated against invasive hemodynamic measurements: (1) 
AMI >40% of the circumference of the LV and (2) left atrial diameter >2.0 mm.185 
Increased lung weight was also an absolute criterion for inclusion in the HF group to 
ensure that only animals with congestion were included in the HF group.  
 
The effect of anesthesia on cardiac function was reduced to a minimum by using oxygen 
and isoflurane supplied via a facemask during the echocardiography. 
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Cardiomyocyte cell culture experiments 
The use of isolated cardiomyocytes in basic cardiovascular research dates back to 1912 
when Burrows first demonstrated that cardiomyocytes could contract in vitro.192 
Cardiomyocytes respond in a similar fashion to external stimuli in vitro as they do in vivo, 
thus making this model relevant for studies of cardiovascular pathophysiology.193 
Neonatal cardiomyocytes, which are not terminally differentiated cells, represent an 
optimal model to assess alterations in growth and gene expression as they show dynamic 
changes to external stimuli and can activate fetal gene expression,194,195 which is a key 
feature of the failing myocardium.196 Analogous to other experimental models, a major 
advantage of using isolated cardiomyocytes is the ability of the researcher to control 
external confounders.  
 
We used neonatal rat (Wistar) cardiomyocytes in papers #III and IV to assess the influence 
by hormones, cytokines, and growth factors on granin gene expression. The ligands that 
were included in our panel are all increased in HF and have previously been shown to 
influence cardiomyocyte gene expression.193 In paper #4, neonatal rat cardiomyocytes 
were also used to explore the effect of the SgII fragment secretoneurin on hydrogen 
peroxide-induced cardiomyocyte apoptosis and on protective intracellular signaling 
pathways.  
 
To obtain pure cultures of neonatal cardiomyocytes, the cell suspension was filtrated 
through a discontinuous Percol gradient after enzymatic digestion.197 During the 
enzymatic digestion of the cells, the cell membrane may be damaged and a recovery 
period is therefore recommended to allow repair of superficial membrane damage and to 
eliminate lethally damaged cells.198 In our experiments, all cells were allowed to recover 
for 24 h prior to the start of experiments. We also visually inspected the cardiomyocytes to 
assess the number and quality of cells. Moreover, positive control ligands were included in 
all experiments to assure that the cells responded in a uniform manner throughout the 
series of experiments. For the studies on granin messenger (m)RNA expression, forskolin 
was used as a positive control as forskolin increase CgB and SgII mRNA synthesis in non-
cardiac cells.199 We also measured proBNP mRNA levels as several of the included 
ligands (norepinephrine, angiotensin II, endothelin-1, etc) are known to increase 
44

cardiomyocyte proBNP synthesis.42 Cells stimulated with PBS served as the control and 
data are presented as the change vs. levels in PBS stimulated cells (fold change).  
 
In paper #4, we used neonatal rat cardiomyocytes to examine the effect of secretoneurin 
on hydrogen peroxide-induced cardiomyocyte apoptosis. For these experiments, cells were 
first exposed to hydrogen peroxide for 24 h, after which a proportion of the cells were co-
incubated with secretoneurin and hydrogen peroxide for 24 h. Cardiomyocyte apoptosis 
was measured by the Cell Death Enzyme-linked Immunosorbent Assay (Cell Death 
Detection ELISAPLUS, Roche, Basel, Switzerland) which detects DNA fragmentation by 
utilizing monoclonal antibodies against DNA and histones, respectively. This system has 
previously also been used by other groups to assess cardiomyocyte apoptosis.200 We 
compared results in cells incubated with hydrogen peroxide and secretoneurin to cells that 
were only incubated with hydrogen peroxide.  
 
Finally, in paper #4 neonatal cardiomyocytes were also used to examine the effect by 
short-term secretoneurin stimulation on phosphorylation of Akt, Erk1/2 and Stat3. In our 
experiments, we incubated cardiomyocytes for 10 or 30 min with secretoneurin and then 
quantitated the phosphorylation status of Akt, Erk1/2 and Stat3, which are the active forms 
of these intracellular signaling molecules.201-203 The effect by secretoneurin was 
determined by comparing phosphorylation status after secretoneurin incubation to baseline 
p-Akt, p-Erk1/2, and p-Stat3 levels. 
 
Ischemia-reperfusion model of the isolated perfused rat heart 
The isolated perfused heart model was introduced by the German physician Oskar 
Langendorff in the late 19th century.204 In the Langendorff model, the heart is excised and 
then perfused in a retrograde fashion via the aorta, which causes the aortic valves to shut. 
After closure of the aortic valves, oxygen and nutrient rich perfusate is propelled into the 
coronary arteries. We used a standard perfusate (Krebs-Henseleit Buffer, KHB) in our 
experiments.  
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Removing the heart from the body can terminally damage the organ and we therefore 
assessed the competence of all hearts before the start of the experimental protocol. Hearts 
with LV systolic pressure 100 mmHg, coronary flow 8 or 20 mL/min, heart rate 220 
beats per minute before ischemia, or irreversible arrhythmias for more than 30 min during 
reperfusion were all excluded. To control for the effect of the model itself on myocardial 
function,205 we implemented a 40 min stabilization period prior to the 30 min of global 
ischemia. After the ischemia, hearts were reperfused for 120 min before the hearts were 
cut in several slices, including segments that were incubated in 1% 
triphenyltetrazoliumchloride (TTC). The TTC stained slices were gently pressed between 
two glass plates and photographed. Secretoneurin was added to the perfusate in the 
secretoneurin group 20 min prior to induction of ischemia and throughout the reperfusion 
method. The end point of the study was infarct size that was calculated in the TTC slices 
by an independent researcher with no knowledge of treatment groups.  
Real-time reverse transcription polymerase chain reaction (RT-qPCR) 
Ribonucleotide acids (RNA) are single or double stranded chains of nucleotides that 
consist of ribose sugar, a phosphate group, and one of the four bases adenine (A), cytosine 
(C), guanine (G), or uracil (U). A special strain of RNA is mRNA, which is responsible 
for the transfer of information from the DNA double strand to protein. This process starts 
with the enzyme RNA polymerase binding to the DNA strand in the promoter region 
upstream of the target gene. RNA polymerase then proceeds in the 5'3' direction to 
synthesize mRNA with DNA as the template.206 The promoter region contains several 
binding sites for transcription factors which regulate mRNA synthesis, thus mRNA 
production is tightly controlled by extra- and intracellular signals.199 After completion of 
mRNA synthesis, the mature mRNA transcript is transported out of the nucleus to the 
cytoplasm.206 In the cytoplasm, by interacting with transfer RNA and ribosomes, the 
mRNA strand is translated into a protein as every 3 nucleotides constitute a codon 
representing the code for a specific amino acid.   
 
The number of mRNA copies represents the activity of specific genes. The current method 
of choice to quantify mRNA levels is real-time reverse transcription polymerase chain 
reaction (RT-qPCR), which is a combination of three steps.207,208 First, total RNA is 
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extracted from samples and the concentration and quality of RNA assessed as described in 
paper #3. We only used RNA with RNA integrity number (RIN)>8 for all samples. The 
next step is to synthesize the complementary (c)DNA strand before any measurements can 
be performed. After cDNA synthesis, we used a primer-and-probe based RT-qPCR system 
(TaqMan assays) from Applied Biosystems (Foster City, CA, USA) to quantify the 
mRNA levels (step 3).  
 
In TaqMan assays, the forward and reverse primers bind to the template cDNA at the 3' 
end of the 3'-5' strand and the 5'-3' strand respectively, while the probe binds to a 
complementary sequence between the forward and reverse primers (annealing). The probe 
is labeled with a reporter dye at one end and a quencher due at the other end which 
absorbs the report dye fluorescent emission.207 During elongation of the new DNA strand 
(extension), the probe is cleaved and the fluorescent dye is separated from the quencher. 
This increases the report dye fluorescent emission spectra which is detected by the thermo 
cycler.207 A new cycle is initiated by increasing the temperature of the thermo cycler, 
which will separate the two DNA strands and make them available for a new cycle of 
annealing and extension. In RT-qPCR experiments, a doubling in DNA strands is 
optimally obtained per cycle. Several rounds of annealing, extension, and denaturation are 
needed to reach the lower limit of detection (threshold). The quantity of mRNA in the 
original sample will determine the number of cycles needed to reach the threshold, and 
genes with low number of copies will require more amplification to reach the threshold 
compared to more abundant genes (e.g. will have a higher Ct= threshold cycle/ Cq= 
crossing point).207,208  
 
A criterion of great importance for RT-qPCR is the efficiency of the qPCR reaction, which 
should always be verified by checking the standard curve.208 In our experiments, the 
efficiency was acceptable for all runs and we only used pre-designed assays which have 
been validated by the producer. Also to ensure stability across different extractions and 
RT-qPCR runs, we included RPL4 analysis in the protocol as this gene is not altered in HF 
(housekeeping gene).209 We found no difference in RPL4 gene expression between HF 
and sham animals in our experiments. 
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1-D gel electrophoresis and immunoblotting 
We used sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) 
according to the Bradford method210 to quantitate and study processing of proteins in our 
experimental models. As reported in the supplementary materials of papers #3 and #4, first 
total protein homogenate is extracted from the samples. SDS is added to the total protein 
homogenate before gel loading, binds to the proteins, and gives the proteins identical 
charge per unit mass. After extraction, denatured sample proteins are loaded onto a gel 
electrophoresis system connected to a power supply. When the power is turned on, an 
electric field is applied across the gel and the proteins will migrate in the gel towards the 
positive charged anode. Small proteins will travel faster towards the anode compared to 
larger proteins. Of note, the granin proteins migrate anomalously on the SDS gel due to a 
relatively high content of acidic residues that will interact with the SDS in the gel 
matrix.80 In addition, post-translational modifications will influence the number and 
position of bands on the gel, which we demonstrate for SgII in paper #4.  
 
After separation of the proteins on the gel, two main strategies can be used to visualize the 
proteins. Staining the gel with Coomassie blue or silver staining is an unspecific method 
that will detect all proteins in the gel. Visible distinct bands will represent either abundant 
expressed proteins or represent a mix of several different proteins with similar molecular 
mass. To characterize the individual proteins after Coomassie blue or silver staining, the 
bands must be cut out from the gel and the amino acid sequence determined by mass 
spectrometry. However, as mass spectrometry can be time consuming and technically 
challenging, immunoblotting represents a more direct method to identify target proteins. 
In immunoblotting, the first step is to transfer the proteins from the gel to a membrane, 
which typically is made of nitrocellulose or PVDF. The membrane is incubated with a 
specific antibody that binds to the target protein (primary antibody). To avoid unspecific 
binding, the membrane is blocked with 5% skimmed milk prior to incubation with the 
primary antibody, and washed several times after each incubation step. Thereafter, the 
membrane is incubated with a secondary antibody conjugated with horseradish peroxidase 
(HRP). The secondary antibody will bind to the primary antibody. Finally, a substrate for 
HRP is added to the membrane and a chemiluminescent signal will be emitted and 
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detected by a ccd camera. The densitometry of immunostained bands was quantified  by 
the Multi Gauge software (Fujifilm, Tokyo, Japan). 
 
The sensitivity and specificity of the primary antibody is crucial for the quality of the 
immunoblot. In paper #3, we tested the specificity of the CgB antibody by co-incubating 
the membrane with a blocking peptide and by mapping the binding site of the antibody as 
previously reported.211 No blocking peptide was available for our SgII antibody, but our 
results in HF animals are supported by data from SgII radioimmunoassay and the data on 
the proteases PC1/3 and PC2, which are increased in HF.  
 
Enzyme-Linked ImmunoSorbent Assay
We used a commercial enzyme-linked immunosorbent assay (ELISA) for CgA 
measurements for papers #1 and #2 (K0025, DakoCytomation, Glostrup, Denmark).100 In 
this double antibody sandwich assay, a known quantity of the capture antibody is affixed 
to the surface of the wells and will bind the antigen of the sample. In the next step, a 
detection antibody is added that binds the antigen of the capture antibody-antigen 
complex, followed by an enzyme-linked secondary antibody which will bind to the 
detection antibody. In the last step, substrate is added that the enzyme can convert to a 
detectable signal. Thus in the case of fluorescence ELISA, when light of the appropriate 
wave length is shone upon the sample, any antigen/antibody complexes will fluoresce so 
that the amount of antigen in the sample can be determined through the magnitude of the 
fluorescence. For quality control, measurements are also carried out on standard samples 
with known concentrations of protein to assess sensitivity and analytical stability. The 
analytical characteristics of an assay are normally presented by reporting the lower limit of 
detection and the coefficient of variation (CV). The CV is calculated by dividing the 
standard deviation by the mean, which should be established by measuring the same 
sample over time. Preferably, to demonstrate stability across the spectrum of analytical 
range, the CV should be reported for different concentrations of the assay. The limit of 
detection of the CgA assay is 7.0 U/L and the upper reference limit according to the 
manufacturer is 18 U/L. The intra- and interassay coefficients of variation are 5 and 10%, 
respectively. 
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Radioimmunoassay
We used radioimmunoassay (RIA) to measure granin proteins in the circulation and tissue 
in the papers #3 and #4. To make a RIA, the first step is to attach a gamma-radioactive 
isotope to a known quantity of the protein.212-214 The radio-labeled protein is then mixed 
with a known amount of the antibody which will result in protein-antibody interaction. 
The next step is to incubate the sample with an unknown quantity of that same protein. 
This causes the unlabeled (or "cold") protein from the sample to compete with the radio 
labeled protein for the antibody binding site. As the concentration of "cold" antigen is 
increased, more of this protein will bind to the antibody, and thus displace the radio 
labeled protein. After several rounds of washing, only protein bound to antibody is 
retained in the well and the radioactivity of the free protein can be measured in the 
supernatant. A binding curve can be plotted based on the concentration of radioactivity in 
the supernatant and the protein levels of the original sample estimated.  
 
To measure the granin proteins, a commercial RIA was available for CgA analysis 
(EuroDiagnostica AB, Malmö, Sweden),100 while we used two in-house RIAs for CgB213 
and SgII analysis214 (from Mats Stridsberg, MD, PhD, University of Uppsala, Uppsala, 
Sweden). The detection limits and the CVs of these assays are reported in paper #4.   
Immunohistochemistry
We used immunohistochemistry in paper #3 and #4 to determine the cellular localization 
of the granin proteins in the myocardium. Tissue samples for immunohistochemistry were 
first incubated overnight in 4% formalin, then washed in 30% ethanol, and later stored in 
70% ethanol at 4°C before use. Slides for immunohistochemistry were prepared by 
standard methods. After incubation with the primary and secondary antibody, the avidin-
biotin-peroxidase system (Vectastain Elite kit, Vector Laboratories, Burlingame, CA, 
USA) was used to further amplify immunoreactivity, before sections were counter-stained 
with hematoxylin. We used non-immune rabbit serum or omitted the primary antibody to 
check for unspecific staining.   
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Summery of results 
Paper #I: 
Circulating CgA levels were measured in 1268 patients admitted with ACS, out of whom 
531 patients (42%) were diagnosed with STEMI, 447 patients (35%) diagnosed with 
NSTEMI, and 290 patients (23%) diagnosed with unstable angina pectoris. We found 
CgA levels to be correlated to several established risk factors in ACS, including age, 
comorbidities, proBNP levels and LVEF. During a median follow-up of 92 months 
(interquartile range 71-110 months), 389 (31%) of the patients died. Our principal finding 
in this study is an independent association between CgA levels and mortality during 
follow-up. This association was evident across the spectrum of ACS and also in subgroups 
of patients in which data on cTnT and proBNP levels and LVEF were available. 
 
 
 
 
Fig 9. Association between chromogranin A levels by quartiles and long-term mortality in 
patients hospitalized for ACS 
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Paper #II: 
Circulating CgA levels were measured in 1233 patients with chronic, stable HF on 
inclusion and after 3 months in the biomarker substudy of the GISSI-HF trial. CgA levels 
were associated with several established risk factors in HF, including autonomic 
dysfunction as measured by heart rate variability in a subgroup of patients with 24 h 
Holter recordings. During a median follow-up of 3.9 years (interquartile range 3.1-4.6 
years), 333 (27%) of the patients died. We found that CgA levels measured on inclusion in 
this GISSI-HF study differentiated between patients with a poor and a favorable outcome. 
However, as CgA levels were influenced by several established risk factors, including age, 
comorbidities, blood pressure, and BNP, the association between CgA levels and mortality 
was attenuated and no longer significant in multivariable analysis. There were no 
interactions between CgA levels and rosuvastatin or n-3 polyunsaturated fatty acids 
therapy. 
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Fig 10. Association between chromogranin A levels by tertiles and long-term mortality in 
patients with stable HF 
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Paper #III: 
Tissue and circulating levels of CgB in HF were examined by the use of experimental 
animal models and patients with HF. In a post-AMI HF mouse model, LV CgB mRNA 
levels were increased in proportion to HF severity as measured by lung weight. CgB 
protein levels were also increased in the failing myocardium, while levels were not altered 
in non-cardiac tissue of HF animals. We also found myocardial CgB production to be 
confined to the cardiomyocytes and that norepinephrine, TGF-, and angiotensin II 
enhanced CgB production in vitro. Finally, in 80 patients with mainly stable HF, 
circulating CgB levels were increased compared to levels in 20 healthy age- and gender-
matched control subjects. CgB levels in HF patients increased in proportion to the severity 
of HF as assessed by NYHA functional class.  
 
 
 
 
 
Fig 11. CgB production is increased in non-infarcted LV tissue of HF animals (left) and 
circulating CgB levels are increased in proportion to the severity of HF (right) 
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Paper #IV: 
Production of SgII was examined in the post-AMI HF mouse model. SgII mRNA and 
protein levels were increased in the LV of HF animals, while we did not observe an 
increase in non-cardiac tissue during HF development. SgII production was confined to 
the cardiomyocytes and increased after norepinephrine and TGF- stimulation. Circulating 
levels of SgII in 58 patients with chronic, stable HF of mainly mild severity were elevated 
compared to levels in age- and gender-matched control subjects. To explore a potential 
role for SgII in post-AMI HF development, a functional fragment of SgII, secretoneurin, 
was added to the perfusate in a global ischemia/reperfusion model of the isolated rat heart. 
We found that secretoneurin reduced infarct size by 30% and attenuated the increase in 
LV end-diastolic pressure seen after ischemia. Secretoneurin also reduced hydrogen 
peroxide-induced cardiomyocyte apoptosis and activated Erk1/2 and Stat3 signaling, 
which supports that secretoneurin plays a role as a protective peptide in HF after 
myocardial infarction.  
 
 
 
 
 
 
Fig 12. SgII immunoreactivity (brown staining) was confined to cardiomyocytes in the 
myocardium (left) and the SgII fragment secretoneurin reduced infarct size after 
ischemia/reperfusion injury 
54

Discussion
The main findings of this thesis are that levels of granin proteins are increased in the LV 
and circulation in HF and that CgA levels provide independent prognostic information in 
patients with ACS. The clinical usefulness of CgA as a biomarker in patients with stable 
HF seems more limited, although we found a close bivariate association between CgA 
levels and mortality. 
 
Production of granin proteins in HF 
The importance of the endocrine function of the heart in HF is well recognized.4,38,157 
Production of several proteins are increased in the failing myocardium, and we have now 
identified the granin protein family as a novel group of proteins that are produced by 
cardiomyocytes in HF. CgA has previously been shown to be localized to cardiomyocytes 
in HF,109 but we now complement and transcends previous reports by demonstrating 
increased cardiomyocyte CgB and SgII production in HF. Recently, increased CgB 
production was also reported in an angiotensin II induced LV hypertrophy mice model133 
and SgII was identified in the healthy rodent myocardium,215 which both support the 
validity of our results. However, by utilizing a translational approach, we are the first to 
demonstrate increased CgB and SgII levels in the myocardium and circulation in HF.   
 
Characterizing the regulatory mechanism of cardiomyocyte gene expression can be 
assessed in experimental models.175,193 We used isolated cardiomyocytes to examine the 
mechanisms responsible for increased granin production in HF. In these experiments, 
norepinephrine and TGF- increased CgB and SgII mRNA levels, while angiotensin II 
only stimulated CgB production. In contrast, we were not able to identify factors that 
increased CgA mRNA levels. The difference in responsiveness of the granin genes to our 
panel of hormones, growth factors, and cytokines can be explained by variations in the 
promoter region of the granins.199 For CgA and CgB, a cAMP responsive element has 
been identified as the crucial regulator of gene expression,152,216 while a serum response 
element is important for SgII expression.217 Other regions in the CgA promoter may also 
influence gene expression,218 which may explain the lack of responsiveness in CgA 
synthesis in our system. Additional strategies should be explored to investigate CgA  
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production in HF that seems to be controlled by other mechanism than CgB and SgII 
expression.  
 
Our data indicate that -adrenergic signalling and the TGF- pathway might induce CgB 
and SgII expression in cardiomyocytes during HF development. However, these data 
should be validated and further explored before any definite mechanism for CgB and SgII 
synthesis in the myocardium can be established. Pertinent to this, hypoxia-inducible 
factor-1 (HIF-1) may also play a role after myocardial ischemia as HIF-1 increase SgII 
production in skeletal muscle after hypoxia.219 The effect of hypoxia on cardiomyocyte 
gene expression was not examined in our models and should be explored in future studies.  
 
HF is a syndrome that affects multiple organs of the body, not just the heart. Pulmonary 
tissue, liver, and the gastrointestinal tract are affected by congestion, while the 
inflammatory response in HF will induce changes in the spleen. Hemodynamic changes 
may also compromise renal function. Accordingly, to provide a comprehensive 
assessment of granin production in HF, we explored granin production also outside the 
heart in our post-AMI HF mouse model. We found the granin proteins to be expressed in 
all organs examined, which is new information compared to data from previous reports,220 
but there was no increase in granin expression in the right ventricle, pulmonary tissue, 
liver, spleen, stomach, colon, or skeletal muscle in animals with HF.  
 
In our post-infarction HF model, we identified CgA, CgB, and SgII mRNA and protein 
levels as increased in the failing myocardium. In paper #4, we were also able to 
demonstrate enhanced processing of full-length SgII to shorter fragments. This could be 
important as the short post-translational modified fragments represent the functional units 
of SgII.221,222 The mechanism for the increased processing in the failing myocardium 
seems to be elevated PC1/3 and PC2 levels, which previously have been identified as the 
major proteases for the granin proteins.83,84 Of note, enhanced processing of SgII to 
shorter fragments in neuroendocrine cells is associated with increased secretion of SgII 
fragments from the cell,223 but we have not measured SgII secretion from cardiomyocytes 
in HF. 
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We lack data on production of granin proteins in the adrenal medulla in HF, which is a 
limitation to our work. However, although the adrenal medulla is considered the principal 
organ for CgA synthesis, the concentration of SgII is much lower in the adrenal 
medulla,224 and the gastrointestinal tract has been proposed as the principal organ 
contributing to circulating SgII levels.221 In our HF animals, no increase in SgII levels was 
observed either in the stomach or in the colon. Moreover, in STEMI patients there are only 
weak or no correlations between CgA and catecholamine levels in the subacute 
phase,162,163 hence supporting a model of several organs contributing to CgA synthesis in 
cardiovascular disease.164 The same model could be relevant for CgB and SgII as these 
proteins are expressed throughout the body and seems to increase in the LV in 
cardiovascular disease. Future studies should establish the principal organs that synthesize 
granin proteins in cardiovascular disease by performing selective sampling across 
different vascular beds in patients with ACS and HF.  
 
Of more general scientific interest, our results identify the granin proteins as proteins that 
are ubiquitously expressed in the body, rather than confined to the cells of the 
neuroendocrine system. We believe the widespread distribution, and the increase in 
production in cells with an endocrine phenotype, support our revised model of granin 
proteins as markers of cells with a high secretory rate. This could also be relevant for other 
conditions with a secretory phenotype during disease progression and provide a common 
denominator for diseases in which granin proteins are markers of disease progress and 
severity.  
 
Functional aspects of granin proteins in cardiovascular disease 
Proteins that are increased in patients with cardiovascular disease could influence 
cardiovascular pathophysiology by a direct effect on the myocardium, or through effects 
on extra-cardiac organs by a paracrine or endocrine mechanism.4,12,24 The granin proteins 
are increased in patients with cardiovascular disease and there is a possibility that these 
proteins could play a causal role in disease progression.  
 
57

Seminal work by other groups have documented effects by the short CgA fragments 
vasostatin II and catestatin on the vasculature and the myocardium.134 These effects 
include enhanced vasodilatation,137 attenuated contractility,109,138,142 improved endothelial 
function,140 reduced catecholamine release,143 and protection from myocardial ischemia-
reperfusion injury147 and excessive -adrenergic and endothelin-1 signaling in 
cardiomyocytes.144,225 The protection of CgA against detrimental -adrenergic drive has 
been proposed as the principal functional aspect of CgA in cardiovascular disease.145,146 
Interestingly, myocardial CgA expression was recently found to decrease during reverse 
remodeling in HF patients that had LV assist device (LVAD) implantation, while there 
was no change in circulating CgA levels.226 This report supports a dynamic regulation of 
CgA in cardiomyocytes during cardiovascular disease, but also highlight the widespread 
production of CgA and the lack of specificity of circulating CgA levels for cardiovascular 
disease. This has also been demonstrated by other groups which found CgA to be a poor 
diagnostic marker for HF in patients hospitalized for dyspnea,227 but a strong prognostic 
marker in the same patients.228,229 There was no significant difference in circulating CgA 
levels between HF patients and healthy control subjects in paper #3 and #4 of this thesis.   
 
Prior to our work, no information was available on the role SgII and the SgII fragment 
secretoneurin play in cardiovascular disease. We now provide evidence that SgII 
expression and processing are increased in HF and that secretoneurin may play a role in 
cardiovascular pathophysiology. The 30% reduction in infarct size after ischemia-
reperfusion injury and the attenuated cardiomyocyte apoptosis suggest a counteractive role 
for secretoneurin in post-infarction HF, but long-term effects of secretoneurin should be 
established before the net effect of increased SgII levels in HF can be determined. This 
also relates to CgB, although CgB previously has been identified as important for 
cardiomyocyte Ca2+ handling and hypertrophy,133 which are relevant in HF.4,12,16,24 Mice 
with CgB deletion123 and overexpression230 have been reported, but no information is 
available on the cardiovascular phenotype of these genetically modified mice. 
Characterizing the cardiovascular phenotype of the CgB gain- and loss-of-function mice in 
the steady-state situation and during stress could provide important information on the role 
of CgB in the myocardium, although cardiospecific mutations would be superior to the 
current whole-body models that have alterations in neuroendocrine function.123 
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Granin proteins as cardiovascular biomarkers 
A large number of proteins have been proposed as new cardiovascular biomarkers (Figure 
4),38,75 but currently the cardiac troponins and the BNPs are the only biomarkers that are 
clinically used in patients with ACS and HF.7,9,18,75 We now propose the granin proteins as 
possible new cardiovascular biomarkers, but only CgA has so far been tested in large 
clinical cohorts.161-163,171,172,226-229 Still, the potential of the granin proteins as 
cardiovascular biomarkers has recently been recognized in authoritative reviews on 
cardiovascular biomarkers.38,75 
  
The granin proteins are reported to have a high signal-to-noise ratio and no need for strict 
pre-analytical handling.99,160 These analytical aspects are imperative for a protein to have 
potential as a clinical useful biomarker (Figure 6).44 Moreover, CgA seems to provide 
incremental prognostic information to established risk indices in patients with acute 
cardiovascular disease,162,163 as also demonstrated in paper #1 of this thesis. CgA was 
recently also found to provide independent prognostic information in patients with acute 
decompensated HF228 and in unselected patients hospitalized for dyspnea,229 but there is 
still a lack of information on the ability of CgA to improve prognostic accuracy and 
reclassification. Future studies should also perform receiver operating statistical analysis 
and model fit before CgA can be considered a strong contender in the on-going 
cardiovascular biomarker race.56 There is also a need to better understand the 
pathophysiology of CgA before this marker can be explored for guiding patient 
management.70 This will require both experimental and clinical studies. The current model 
links CgA to -adrenergic drive95-97,145,146 and it should be assessed whether CgA could be 
useful for titration of -adrenergic blocker therapy in patients with cardiovascular disease. 
However, this should first be addressed in experimental models and by propensity score 
statistics231 in established clinical cohorts.  
 
Our data identify CgA as a potential clinical relevant prognostic biomarker in the acute 
setting. The mechanism for the superior prognostic information of CgA in acute patients 
vs. stable patients could relate to a larger contribution by the adrenal medulla, and 
possibly the myocardium, to circulating CgA levels in the acute setting compared to stable 
patients. By providing integrated information on neuroendocrine activity and the 
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myocardium, CgA could provide information on pathophysiology currently not 
implemented in established risk indices. However, the association with neuroendocrine 
tone will reduce the potential of CgA as a diagnostic biomarker in cardiovascular disease 
and this has also been demonstrated by other groups.227 Interestingly, although not a good 
marker for diagnosing HF in patients with dyspnea, CgA was still a powerful prognostic 
biomarker in the same cohort of patients.229 CgA thus seem useful to identify a subgroup 
of patients with similar phenotype and for risk assessment in the acute setting, but will not 
help in diagnosing HF per se. Other groups have also found CgA232 to provide 
independent prognostic information in patients with critical illness, and CgA is more a 
biomarker of disease severity than a marker associated with a specific organ dysfunction. 
We recently explored this further by demonstrating superior information by CgA over NT-
proBNP and troponin T as measured by a highly sensitive (hs) assay for the prediction of 
hospital mortality in patients with severe sepsis.233 Of note, in this study we also found 
CgA levels associated with previous cardiac disease and indices of cardiovascular stability 
such as cardiovascular SOFA score on day 3 and septic shock during the hospitalization. 
The incremental prognostic information by CgA in this study, including in analysis that 
adjusted for established risk scores in sepsis, indicates that CgA represents 
pathophysiology currently not covered by established risk indices and cardiac biomarkers. 
The strong and indepedent information by CgA in patients with AMI and acute HF was 
also supported by a post hoc analysis from the OPTIMAAL trial in which 37 circulating 
biomarkers have been measured.234 By exploratory factorial analysis CgA was clustered 
together with 8 other biomarkers as the most powerful predictors of all-cause mortality 
and the combined end point of cardiovascular death or non-fatal recurrent AMI. 
Interestingly, there was only moderate correlations between CgA levels and the levels of 
the other biomarkers (r<0.4), thus CgA does not seem to duplicate information that can be 
attained from clinical examination, echocardiography, or by measuring other cardiac 
biomarkers. Future studies should progress our understanding of the association between 
CgA levels, adrenergic tone, and cardiovascular disease. Moreover, although not 
correlated with the increment in hs-cTnT levels during long-distance running,235 this 
should not be used to prelude an association between CgA levels and cardiac burden 
during exercise as hs-cTnT elevations do not seem closely correlated with cardiac 
pathology.236 Finally, to promote CgA as a clinical relevant biomarker, we need more 
60

information on the association between CgA levels and medication and the merit of CgA 
to guide patient management.     
 
There is minimal information currently available on CgB and SgII as biomarkers and no 
conclusions can be made regarding their potential in cardiovascular disease although CgB 
is considered an attractive candidate also by other groups.237 We demonstrate a significant 
increase in circulating CgB and SgII levels in patients with HF compared to age- and 
gender-matched control subjects. CgB was also found to increase in proportion to the 
severity of HF as assessed by the NYHA functional class. There was a more robust 
increase of CgB and SgII levels over CgA levels in the HF patients of papers #3 and #4, 
but whether this relates to a larger contribution by the myocardium to circulating CgB and 
SgII levels remains to be established. Future studies should focus on the pathophysiology 
of these proteins in cardiovascular disease and the diagnostic and prognostic merit in ACS 
and HF patients. Although we find that the SgII fragment secretoneurin attenuates 
ischemia-reperfusion injury and cardiomyocyte apoptosis, this does not preclude that 
additional pathophysiology could be more relevant for SgII as a cardiovascular biomarker. 
Pertinent to this, our data in isolated cardiomyocytes link SgII expression to 
norepinephrine and TGF- signalling, while angiotensin-II stimulation also increased CgB 
mRNA levels.  
 
The role CgB plays in cardiovascular disease is not established. Previous work have 
linked CgB to Ca2+ handling and LV hypertrophy in the myocardium,133 but the 
mechanism for, and the net effect of, elevated CgB levels in HF have yet to be determined. 
The widespread production of CgB and SgII in the body (papers #3 and #4) also suggests 
that these proteins could be markers of extra-cardiac pathophysiology, including 
adrenergic tone that has been demonstrated for CgA. In contrast, there does not seem to be 
a close correlation between BNP and granin levels in patients with HF (paper #4). More 
surprisingly, the individual granin proteins neither seem to be closely correlated in patients 
with HF (paper #4). Accordingly, the granin proteins should be considered separate 
biomarkers in cardiovascular disease, and they do not appear to duplicate the information 
from BNP in HF patients. Future research, which should combine clinical studies and 
experimental work in cells and animals, will increase our understanding of the 
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pathophysiology of these proteins and provide more data on CgA, CgB, and SgII as new 
cardiovascular biomarkers.   
Conclusion
We have demonstrated that CgA provides independent prognostic information in patients 
with ACS (paper #1), while the role of CgA as a biomarker in patients with stable HF 
seems more limited (paper #2). The two other principal granin proteins, CgB and SgII, are 
increased in the LV and circulation in HF (paper #3 and #4), but currently limited 
information is available concerning the functional aspects and the utility of these proteins 
as cardiovascular biomarkers. The SgII derived fragment secretoneurin protects against 
myocardial ischemia-reperfusion injury and cardiomyocyte apoptosis, but long-term 
effects of elevated SgII levels in HF have not been assessed. Accordingly, although our 
data identify CgA, CgB, and SgII as an interesting group of proteins in cardiovascular 
disease, more basic and clinical research are needed to determine the pathophysiological 
role these proteins play in ACS and HF and the potential of the granin proteins as 
cardiovascular biomarkers. 
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Aims To determine whether circulating levels of chromogranin A (CgA) provide prognostic information independently of
conventional risk markers in acute coronary syndromes (ACSs).
Methods
and results
We measured circulating CgA levels on day 1 in 1268 patients (median age 67 years, 70% male) with ACS admitted to
a single coronary care unit of a Scandinavian teaching hospital. The merit of CgA as a biomarker was evaluated after
adjusting for conventional cardiovascular risk factors. During a median follow-up of 92 months, 389 patients (31%)
died. The baseline CgA concentration was strongly associated with increased long-term mortality [hazard ratio per 1
standard deviation increase in logarithmically transformed CgA level: 1.57 (1.44–1.70), P, 0.001], heart failure hos-
pitalizations [1.54 (1.35–1.76), P, 0.001], and recurrent myocardial infarction (MI) [1.27 (1.10–1.47), P, 0.001],
but not stroke. After adjustment for conventional cardiovascular risk markers, the association remained signiﬁcant
for mortality [hazard ratio 1.28 (1.15–1.42), P, 0.001] and heart failure hospitalization [hazard ratio 1.24
(1.04–1.47), P ¼ 0.02], but not recurrent MI.
Conclusion CgA is an independent predictor of long-term mortality and heart failure hospitalizations across the spectrum of
ACSs and provides incremental prognostic information to conventional cardiovascular risk markers.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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During the past decade, major progress has been made in the man-
agement of patients with acute coronary syndromes (ACSs). In
parallel with advances in medical therapy and increasing use of
an early invasive strategy, there has been focus on early risk stra-
tiﬁcation of patients, and in particular, the potential prognostic
utility of circulating biomarkers.1 Currently, cardiac-speciﬁc tropo-
nins and B-type natriuretic peptide are the major routinely
measured circulating biomarkers in patients with ACSs.2,3
Chromogranin A (CgA) is a 439 amino acid, 49 kDa polypeptide,
which has been identiﬁed throughout the endocrine and nervous
systems.4 Markedly elevated plasma levels have been observed in
patients with neuroendocrine tumours,5 such as pheochromocy-
toma6 and carcinoid,7 and the clinical application of CgA measure-
ments has so far been limited to diagnosis and follow-up of patients
with such tumours. However, circulating CgA levels also correlate
closely with increased sympathetic activity both in the adrenal
medulla and the peripheral nerve endings,8–10 suggesting that cir-
culating CgA may integrate neuroendocrine signals from various
sources and thus represent an index of overall neuroendocrine
activity. Moreover, myocardial production of CgA in humans
with dilated and hypertrophic cardiomyopathy has recently been
demonstrated,11 and CgA has been shown to increase in
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proportion to clinical severity and to be associated with prognosis
in patients with both chronic and post-infarction heart failure.12,13
In a small population with predominantly ST-elevation myocardial
infarction (MI), we have previously reported a univariable associ-
ation between CgA levels and long-term survival,14 but because
of modest study power, it remains unclear whether CgA is an inde-
pendent predictor of survival. In patients with unstable angina and
non-ST-elevation MI, no prognostic data are currently available.
Because increased neuroendocrine activity may be related to
potentially harmful pathophysiological processes in patients with
both ST-elevation and non-ST-elevation ACS, including endothelial
dysfunction and activation of pro-inﬂammatory cytokines, we
hypothesized that circulating CgA levels would be predictive of
the incidence of death and non-fatal cardiovascular events across
the spectrum of ACS and would provide prognostic information
independently of conventional risk markers, including objective
measures of left ventricular dysfunction and contemporary
cardiac biomarkers.
Methods
Study design
Patients with ACS, deﬁned as a diagnosis of unstable angina,
non-ST-elevation MI, or ST-elevation MI, admitted to the coronary
care unit (CCU) of the Sahlgrenska University Hospital, Gothenburg,
Sweden during the period mid-September 1995 to mid-March 2001,
were eligible for participation in a prospective risk stratiﬁcation pro-
gramme, PRACSIS (Prognosis and Risk in Acute Coronary Syndromes
in Sweden),15 in which the main study exclusion criteria were age ,18
or 80 years, non-coronary artery disease associated with a life expect-
ancy ,1 year, residence outside the city of Gothenburg, unwillingness to
participate, and prior admission resulting in inclusion in the study.
During this 5.5-year period, a total of 2335 patients were included in
the PRACSIS programme. Until November 1995, only clinical infor-
mation was collected in PRACSIS and we did not perform consecutive
serum sampling, resulting in only six random morning pilot serum
samples being drawn in this period. Thereafter, serum for later analysis
was obtained the ﬁrst morning after admission to the CCU in the
patients who, at this stage, were assigned a diagnosis of ACS. Thus, a
number of patients were not eligible for blood sampling despite later
being considered as having ACS and noted as such. Another portion
of patients (n ¼ 612) in PRACSIS were transferred to the CCU from
an internal medicine ward where they had been admitted owing to an
initially uncertain ACS, or from the intensive care unit where they
were admitted owing to the need of mechanical ventilation. We lack
serum from a majority of these patients. Yet another portion of patients
did not survive until the ﬁrst morning in hospital or were at this time
undergoing angiography, and during some holidays serum sampling
was not attempted. These patients were included in the PRACSIS pro-
gramme, but not in the biomarker substudy. Users of proton pump
inhibitors on admission (n ¼ 38) were also excluded from this study,
as proton pump inhibitors are known to increase circulating CgA
levels.16 Thus, the ﬁnal study group comprised 1268 patients.
The primary outcome measure was mortality from all causes. The
median follow-up for this primary endpoint was 92 (interquartile
range 71–110) months (until 1 January 2007). Survival conﬁrmation
and date of death were obtained from the Swedish National Popu-
lation Registry. Eleven patients, who emigrated from Sweden, were
lost to follow-up and censored at the day of emigration.
Pre-speciﬁed secondary outcome measures were the incidence of
the following separate morbidity endpoints: heart failure [International
Statistical Classiﬁcation of Disease, Ninth Revision (ICD-9) code 428
or ICD-10 code I50], acute MI (ICD-9 code 410 or ICD-10 code
I21 or I22), and stroke (ICD-9 codes 431, 432, 433, or 436 or
ICD-10 codes I61, I62, I63, or I64). These data were obtained from
the Swedish Hospital Discharge Register. Because of a slower conﬁr-
mation process than for mortality data, morbidity data were not
available after 31 December 2002. Accordingly, the median follow-up
period for morbidity data was 50 (interquartile range 32–65) months.
For quality control purposes, morbidity data from the Registry were
checked against information in the patients’ medical records by a
cardiologist (M.H.) blinded to biomarker results. No patient was
excluded owing to missing data for outcome.
Patients were prospectively classiﬁed according to Killip class on
admission and during the index hospitalization. Electrocardiographic
ﬁndings on admission were classiﬁed according to the presence or
absence of ST-segment elevation and ST-segment depression. On
the basis of hospital records and personal interview, patients were
classiﬁed as having or not having a history of MI, angina pectoris,
chronic heart failure, diabetes mellitus, or hypertension. The study
protocol was approved by the Regional Ethics Committee before
the initiation of the study. Informed consent was obtained from all
participating patients.
Blood sampling procedures
and echocardiography
Peripheral venous blood was obtained within 24 h of admission by
direct venipuncture of an antecubital vein after the patients had been
supine for .30 min. Blood samples for CgA determination were
drawn into serum tubes and centrifuged within 1 h. Blood samples for
the determination of pro-B-type natriuretic peptide (proBNP) were
drawn into pyrogen-free tubes with EDTA as anticoagulant, immediately
immersed in ice water, and centrifuged within 1 h.
All serum samples were stored at 2708C pending analysis. Plasma
and serum samples had been thawed twice prior to CgA analysis.
However, CgA is considered to be stable in vitro at room temperature
and plasma levels are not inﬂuenced by repeated thawing–refreezing
cycles.17 Echocardiographic investigation was performed by an experi-
enced investigator within 5 days of hospital admission, as described
previously.18,19
Biochemical analyses
CgA in serum was measured by a commercially available ELISA assay
(code K0025, DakoCytomation, Glostrup, Denmark). The detection
limit of the assay was 7.0 U/L, and the intra- and interassay coefﬁcients
of variance were ,5 and 10%, respectively. According to the manufac-
turer, the upper reference limit is 18 U/L. Troponin T and creatine
kinase MB fraction in serum were measured on a modular platform
(Roche Diagnostics, Mannheim, Germany). Troponin T levels were
unavailable in 225 subjects, as troponin T measurement was not part
of the clinical routine during the ﬁrst inclusion period. ProBNP3–108
was measured using immunoﬂuorescent assays calibrated with spiked
plasma (Biosite Inc., San Diego, CA, USA).20 The minimal detectable
concentration was 400 ng/L and the upper range 30 000 ng/L. All
samples were run in duplicate in a blinded fashion. Creatinine and
total cholesterol concentrations in serum were determined by
routine laboratory methods. Creatinine clearance rate (mL/min) was
estimated (estimated glomerular ﬁltration rate, eGFR) using the Cock-
croft–Gault formula,21 as [(1402age)  weight (kg)/serum creatinine
(mmol/L)] multiplied by a constant of 1.23 in men and 1.04 in women.
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Statistical methods
Categorical variables were reported as proportions and continuous
variables as median or mean values. The association between CgA
and baseline demographic variables and cardiovascular risk factors was
assessed by the Mann–Whitney U test and Spearman rank correlation
(rs) for categorical and continuous variables, respectively. To visualize
the relationship between CgA quartiles and mortality, Kaplan–Meier
plots were generated. Cox proportional hazards regression analyses
were used to calculate crude and adjusted risk estimates associated
with a 1 standard deviation (SD) increase in logarithmically transformed
CgA levels for the primary endpoint: mortality from all causes, as well as
for the following individual secondary endpoints: hospitalizations for
heart failure, recurrent MI, and stroke. Adjustments were made for
the following confounders: age (continuous), gender, index diagnosis,
smoking status, prior MI, angina pectoris, diabetes, hypertension,
heart failure, Killip class (dichotomous, i.e. cutoff Killip class .1),
eGFR (continuous, logarithmically transformed), heart rate (continuous,
logarithmically transformed), and peak creatine kinase-MB (continuous,
logarithmically transformed). In addition, adjustments were also made
for troponin T, left ventricular ejection fraction, and proBNP (all
continuous and logarithmically transformed) in the cohorts where
such measurements were available.
The assumption of proportional hazards was assessed by studying
whether interaction terms between the logarithm of time and covari-
ates signiﬁcantly improved the 22 log-likelihood of the model. The
assumption was met for all variables in all models, except for the end-
point rehospitalization owing to heart failure, where previous MI and
creatine kinase-MB showed a slight non-proportionality in the total
cohort, and index diagnosis and creatine kinase-MB in the cohort
with troponin T measurements available. Inclusion of the time-
dependent covariates into the corresponding models above resulted
in only minor changes of the hazard ratios for CgA. We therefore
decided to use the original models in order to cohere with our pub-
lished reports on other markers from the same cohorts and to
adjust for the same covariates in the different endpoint analyses.
Similarly, the assumption of linearity for continuous variables was
checked by entering the squared transformations of the variables
into the models. A signiﬁcant change in the 22 log-likelihood for
any model was considered a sign of non-linearity. All variables met
the assumption of linearity in all models, except for age, regarding
the endpoint rehospitalization owing to MI in the total cohort and
regarding rehospitalization owing to stroke in the three other
cohorts. Also, eGFR showed sign of non-linearity regarding heart
failure in the cohort where troponin T, ejection fraction, and
proBNP were available. For these models, we analysed the hazard
ratios for CgA when the corresponding transformations were
entered into the model, which resulted in only small changes from
the original models, and, for the same reasons as for non-
proportionality, we decided to use the models without squared
transformation of these covariates.
Our primary objective variable CgA did not show any sign of
non-proportionality or non-linearity.
Hazard ratios are given with 95% conﬁdence intervals. All P-values
are two-tailed and considered signiﬁcant if ,0.05.
Results
Baseline characteristics
A total of 1268 patients (median age 67 years, 70% male) had
blood samples for CgA determination obtained within 24 h of
admission and were not users of proton pump inhibitors at the
time of admission. The baseline characteristics of patients accord-
ing to CgA quartiles are presented in Table 1, where also data on
the entire PRACSIS population are given for comparison. Patients
with higher CgA values were more likely to be older, to have lower
body mass index, to have clinical evidence of heart failure, a history
of MI, angina, congestive heart failure, or diabetes mellitus; to be
diuretic users, angiotensin-converting enzyme-inhibitor or
angiotensin receptor blocker users, statin users, or aspirin users
(data not shown); and to have a low ejection fraction or low
eGFR. There was no relation between CgA and troponin T or
creatine kinase MB fraction in serum. A signiﬁcant correlation
(rs ¼20.43, P, 0.001) between eGFR and CgA indicated that
renal function inﬂuenced the CgA level. On the other hand, the
lack of correlation between CgA and troponin T values (rs ¼
0.03, P ¼ 0.18) indicated that myocardial necrosis was not a
major explanation for increased CgA levels. There were no signiﬁ-
cant differences in CgA levels between female and male patients.
There was no signiﬁcant interaction between index diagnosis and
CgA regarding outcome. Accordingly, we decided not to analyse
these groups separately.
Chromogranin A and long-term
mortality
During a median follow-up of 92 months (interquartile range 71–
110 months), 389 patients died. CgA serum levels at baseline were
closely associated with long-term, all-cause mortality [hazard ratio
per 1 SD increase in logarithmically transformed CgA levels: 1.57
(1.44–1.70), P, 0.001]. The Kaplan–Meier survival curves by
CgA quartiles are depicted in Figure 1. After adjustment for con-
ventional risk factors, CgA remained independently associated
with mortality [hazard ratio per 1 SD increase in logarithmically
transformed CgA levels: 1.28 (1.15–1.42), P, 0.001] (Table 2).
CgA levels were also an independent predictor of mortality in the
subgroup of patients in whom troponin T levels were available
and adjusted for in addition to the covariates in the ﬁrst model
[n ¼ 1043; HR 1.27 (1.13–1.42), P, 0.001]. In the group where
left ventricular ejection fraction was determined (n ¼ 824), CgA
was as an independent predictor of all-cause mortality after adjust-
ment for conventional cardiovascular risk factors, troponin T levels,
and echocardiographically assessed left ventricular ejection fraction
[HR 1.26 (1.10–1.44), P, 0.001]. In the group where also data
on proBNP were available and additionally adjusted for (n ¼ 709),
a signiﬁcant predictive value of CgA was also noted [HR 1.18
(1.01–1.37), P ¼ 0.04]. Patients with both CgA and proBNP in the
highest quartiles had an especially poor prognosis (Figure 2).
Chromogranin A and non-fatal
cardiovascular events
By univariable analyses, the baseline CgA concentration was strongly
associated with the incidence of heart failure hospitalizations [hazard
ratio 1.54 (1.35–1.76), P, 0.001] and recurrent MI [hazard ratio
1.27 (1.10–1.47), P, 0.001], but not stroke [hazard ratio 1.16
(0.93–1.46), P ¼ 0.19] (Table 2). After adjustment for conventional
risk factors, CgA remained independently associated with the
incidence of heart failure hospitalizations [hazard ratio 1.24
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(1.04–1.47), P ¼ 0.02], whereas the association with recurrent MI
was attenuated [hazard ratio 1.15 (0.96–1.36), P ¼ 0.12] (Table 2).
In the subgroup where troponin T was available and adjusted for,
CgA was signiﬁcantly associated with both the incidence of heart
failure (P ¼ 0.04) and MI (P ¼ 0.04). However, in the subsample
of patients with echocardiographic data (n ¼ 824), these associ-
ations were attenuated and no longer signiﬁcant after adjustment
for left ventricular ejection fraction (Table 2).
Discussion
The new information obtained from the present study is that
plasma levels of CgA in the acute phase proved to be an indepen-
dent predictor of all-cause mortality in patients with ACSs after
adjustment for conventional risk factors, troponin T levels,
echocardiographically assessed left ventricular ejection fraction,
and proBNP. CgA levels were also associated with heart failure
hospitalizations during follow-up independently of conventional
risk factors, including troponin T. However, in the subsample of
Figure 1 Association between chromogranin A (CgA) levels by
quartiles and all-cause mortality in patients with acute coronary
syndromes.
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Table 2 Associations between chromogranin A concentrations and events during follow-up in patients with acute
coronary syndrome
Endpoint Unadjusted Adjusted
HRa (95% CI) P-value HRa (95% CI) P-value
Total cohort (n ¼ 1268)
Mortality 1.57 (1.44, 1.70) ,0.001 1.28 (1.15, 1.42)b ,0.001b
Heart failure 1.54 (1.35, 1.76) ,0.001 1.24 (1.04, 1.47)b 0.02b
Recurrent MI 1.27 (1.10, 1.47) ,0.001 1.15 (0.96, 1.36)b 0.12b
Stroke 1.16 (0.93, 1.46) 0.19 0.96 (0.73, 1.26)b 0.76b
With troponin T (n ¼ 1043)
Mortality 1.56 (1.43, 1.71) ,0.001 1.27 (1.13, 1.42)c ,0.001c
Heart failure 1.46 (1.26, 1.71) ,0.001 1.23 (1.01, 1.49)c 0.04c
Recurrent MI 1.31 (1.12, 1.52) ,0.001 1.21 (1.00, 1.47)c 0.04c
Stroke 1.18 (0.92, 1.51) 0.19 0.96 (0.71, 1.29)c 0.77c
With troponin T and LV ejection fraction (n ¼ 824)
Mortality 1.56 (1.41, 1.74) ,0.001 1.26 (1.10, 1.44)d ,0.001d
Heart failure 1.33 (1.10, 1.61) 0.004 1.12 (0.88, 1.42)d 0.36d
Recurrent MI 1.31 (1.10, 1.57) 0.003 1.17 (0.95, 1.45)d 0.14d
Stroke 1.16 (0.86, 1.57) 0.34 0.91 (0.62, 1.33)d 0.62d
With troponin T, LV ejection fraction, and proBNP (n ¼ 709)
Mortality 1.53 (1.36, 1.72) ,0.001 1.18 (1.01, 1.37)e 0.04e
Heart failure 1.34 (1.07, 1.36) 0.009 1.11 (0.85, 1.45)e 0.45e
Recurrent MI 1.22 (1.00, 1.49) 0.052 1.10 (0.86, 1.39)e 0.45e
Stroke 1.30 (0.95, 1.78) 0.10 1.01 (0.68, 1.48)e 0.97e
aHR, hazard ratio per 1 SD pg/mL increase in the natural logarithm of CgA.
bAdjusted for age, gender, index diagnosis, smoking status, prior MI, angina pectoris, diabetes, hypertension, congestive heart failure, heart rate, Killip class (.I) on admission,
eGFR, and peak creatine kinase MB fraction.
cAdjusted for all variables listed in footnote b and troponin T.
dAdjusted for all variables listed in footnote b and troponin T and LV ejection fraction.
eAdjusted for all variables listed in footnote b and troponin T and LV ejection fraction and proBNP.
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patients with echocardiographic data, the association was attenu-
ated and no longer signiﬁcant after adjustment for left ventricular
ejection fraction. Potential reasons for the lack of a statistically
signiﬁcant independent association with heart failure in this sub-
sample include the relative lack of statistical power and the
fact that systolic dysfunction is a very strong predictor of heart
failure. The association between CgA and recurrent MI was also
attenuated after adjustment for conventional risk factors, but was
borderline signiﬁcant in patients in whom troponin T values
were available.
In addition to its strong prognostic merit, several practical features
makeCgA apromising biomarker for clinical use, e.g. that its long in vivo
half-life results in relatively high circulating concentrations. This feature
simpliﬁes blood collection and pre-analytic handling and makes CgA
less prone to rapid ﬂuctuations in circulating concentrations (low
signal-to-noise ratio) than many other neurohormones.17 Moreover,
biochemical analysis of CgA can be readily performed using standar-
dized and well-validated, commercially available assays.22
The two main causes of death in patients with ACSs are (i)
recurrent ischaemic events, manifested as an ACS or sudden
death, and (ii) heart failure, which may cause pulmonary conges-
tion, inadequate tissue perfusion, or malignant arrhythmias.
Although the univariable association between CgA and heart
failure was closer than the associations between CgA and MI in
the total cohort, in adjusted models the associations were of
similar strength, permitting no clear conclusion to be drawn as
to whether the prognostic value of CgA is mediated predominantly
via prediction of heart failure or ischaemic events.
A potential link between the CgA and a propensity to heart
failure development remains to be documented. However, theor-
etical considerations suggest that CgA is not only a marker of
neuroendocrine activity, but may in itself exert harmful actions
on the myocardium. CgA is a pro-hormone with multiple proteo-
lytic cleavage sites,4 allowing the generation of several peptides
with different actions such as vasodilation,23,24 negative inotropic
actions,25 inhibition of catecholamine secretion,26 and induction
of apoptosis.27,28 Accordingly, some of the CgA-derived fragments
could have effects of importance for cardiovascular homeostasis
and the heart failure development, including catestatin, a potent
non-competitive inhibitor of catecholamine release.29 In a knock-
out mouse model, obliteration of CgA gene expression resulted
in decreased size and number of chromafﬁn granules as well as
arterial hypertension and ventricular hypertrophy, whereas trans-
genic expression of human CgA and exogenous injection of
human catestatin restored blood pressure.30 These ﬁndings
suggest that CgA and catestatin may play a signiﬁcant role in
cardiovascular homeostasis.
The stimulus for CgA production and the pathophysiological
role CgA plays in ACSs remain to be accurately deﬁned. Acute
ischaemia and subsequent left ventricular dysfunction are both
characterized by complex neuroendocrine and immune activation,
and may both represent potential correlates of CgA production.
Accordingly, the magnitude of the CgA response in ACSs may
be related to the initial extent of myocardial injury and subsequent
degree of ventricular dysfunction. It is also conceivable that CgA
production is a compensatory response to the immune activation
associated with ischaemia and heart failure development. Accord-
ingly, in a mouse model, it has recently been demonstrated that
CgA and its amino terminal fragments inhibit tumour necrosis
factor a-induced increase in vascular permeability by preventing
re-arrangement of the cytoskeleton,31,32 suggesting that CgA
could contribute to the regulation of endothelial barrier function.
The source of increased circulating levels of CgA in ACSs is not
clear. CgA has been detected in the atrial secretory granules con-
taining atrial natriuretic peptide,33 and recently myocardial pro-
duction of CgA in humans with dilated and hypertrophic
cardiomyopathy has been demonstrated,11 suggesting that CgA
may be released from the myocardium in conditions characterized
by pressure or volume overload. However, this does not rule out
the possibility that other organs, including the adrenals, may be
contributing sources to increased levels of CgA. Reduced clear-
ance of CgA may also result in higher circulating levels.34 Arterial
and venous blood sampling across vascular beds will be required
to determine organ-speciﬁc production and clearance of CgA.
Strengths and limitations
The prospective, observational design, long duration of follow-up,
and, in a considerable proportion of patients, echocardiographic
information concerning left ventricular systolic function and
proBNP are all important strengths of the current single-centre
study. In particular, objective measures of left ventricular systolic
function are not commonly obtained or adjusted for in biomarker
substudies of major pharmaceutical multi-centre trials in patients
with ACSs. Limitations include the lack of troponin T, echocardio-
graphic data, and/or proBNP in part of the patients, mainly because
blood sampling was not performed systematically in the early
phase of the study, and because echocardiography was not always
feasible in patients who were discharged early. As data may not
be missing completely at random, we cannot rule out the possibility
of some extent of selection bias. However, given that the hazard
ratio estimates do not vary widely between models, we believe
that the bias is likely to be minor. Moreover, direct comparison of
the hazard ratios of the different multivariate models in Table 2
Figure 2 Association between chromogranin A (CgA) and
pro-B-type natriuretic peptide (proBNP) levels by combined
quartiles (q) and all-cause mortality in patients with acute coron-
ary syndromes.
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should be avoided. There was relatively modest power to detect
associations between CgA and speciﬁc morbidity endpoints.
However, we believe that these limitations will tend to under-
estimate, rather than overestimate, the prognostic value of CgA.
Conclusions
This study shows that plasma CgA levels obtained within the ﬁrst
24 h of admission are independently associated with the incidence
of death in patients with ACS. Clinical use of CgA measurements
for risk stratiﬁcation purposes in patients with ACS must,
however, await conﬁrmatory evidence from other studies.
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Aortoesophageal ﬁstula, a catastrophic complication soon after successful
repair of an aortic dissection type A
Herminia Torrado*, Josep L. Ventura, and Elisabet Farrero
Cardiac Surgery Intensive Care Unit, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Barcelona 08907, Spain
* Corresponding author. Tel: þ34 932 607 923, Fax: þ34 932 607 963, Email: 27672hts@comb.es/minuca_t@hotmail.com
A 66-year-oldmanwith a historyof arterial hyperten-
sion underwent emergency cardiac surgery for aortic
dissection type A, diagnosed by a computed tomo-
graphic scan (Panel A) after abdominal pain and
syncope. The lesion was repaired with a Dacron
tubular prosthesis. In the postoperative period, he
improved his condition slowly under mechanical ven-
tilation and inotropic support. At postoperative day
12, he was awake with minimum inotropic support
and in weaning from mechanical ventilation.
Suddenly, he presented massive haematemesis.
Under the suspicion of an aorto-oesophageal
ﬁstula, an urgent upper gastrointestinal endoscopy
was performed, showing active bleeding at 36 cm
from the dental arcade.
Resuscitation required transfusion of 13 packed
red blood cells, four units of fresh frozen plasma,
and seven units of platelets.
A Sengstaken–Blackmore tube was inserted in
order to contain the bleeding, which was successful
for a while.
After stabilization, an aortogram was performed
(Panels B–D), which revealed contrast leak with
active bleeding in the descending thoracic aorta
from the true lumen to the oesophagus, at the level
of the gastric balloon of the Sengstaken tube which
was placed at the oesophagus (Panel C).
The placement of an endovascular stent graft was
impossible because of the extensive lesions in the
aortic wall.
The patient died 15 h after the initial bleeding, in a situation of refractory shock and persistent bleeding.
Aortoesophageal ﬁstula is an uncommon complication in the early postoperative period of aortic dissection type A, usually fatal as a
result of exsanguinating haemorrhage before assessment and any treatment can be undertaken.
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org.
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ABSTRACT 
Background: Several beneficial effects have been demonstrated for secretogranin II (SgII) in 
non-cardiac tissue. As cardiac production of chromogranin A and B, two related proteins, is 
increased in heart failure (HF), we hypothesized that SgII could play a role in cardiovascular 
pathophysiology. 
Methodology/Principal findings: SgII production was characterized in a post-myocardial 
infarction heart failure (HF) mouse model, functional properties explored in experimental 
models, and circulating levels measured in patients with stable HF of moderate severity. SgII 
mRNA levels were 11.5 fold upregulated in the left ventricle (LV) of animals with myocardial 
infarction and HF (p<0.001 vs. sham-operated animals). SgII protein levels were also 
increased in the LV, but not in other organs investigated. SgII production was confined to 
cardiomyocytes, and potently induced by transforming growth factor- and norepinephrine 
stimulation in vitro. Processing of SgII to shorter peptides was enhanced in the failing 
myocardium due to increased levels of the proteases PC1/3 and PC2. Examining a 
pathophysiological role of SgII in myocardial infarction and HF, the SgII fragment 
secretoneurin reduced myocardial ischemia-reperfusion injury and cardiomyocyte apoptosis 
by 30% and rapidly increased cardiomyocyte Erk1/2 and Stat3 phosphorylation. Circulating 
levels of SgII were higher in HF patients than in control subjects: 0.16 (Q1-3 0.14-0.18) vs. 
0.12 (0.10-0.14) nmol/L, p<0.001.  
Conclusions: We demonstrate increased myocardial SgII production and processing in the 
LV in animals with myocardial infarction and HF, which could be beneficial as the SgII 
fragment secretoneurin protects from ischemia-reperfusion injury and cardiomyocyte 
apoptosis. Circulating SgII levels are also increased in patients with HF and may represent a 
new cardiac biomarker. 
 
 
 
Key words: Heart failure, molecular biology, ischemia, secretogranin II, secretoneurin, 
biological markers 
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INTRODUCTION 
Heart failure (HF) is associated with changes in systemic and pulmonary hemodynamics, 
complex neurohumoral activation, as well as local molecular alterations in the myocardium 
[1]. Given that coronary artery disease is a leading cause of HF [1], a better understanding of 
the pathophysiology of myocardial ischemia and HF development is needed. Regulation of 
hormonal factors in the failing myocardium can directly affect function and survival of 
cardiac cells [1], and result in increased circulating levels of proteins secreted from the 
myocardium [2]. Thus, by identifying proteins that are regulated in the failing myocardium, 
we may enhance our understanding of the pathophysiology of HF and discover new 
diagnostic and prognostic HF biomarkers. 
 
The protein secretogranin II (SgII) is a 587 amino acid long protein from the chromogranin-
secretogranin (granin) protein family [3]. Two other members of the granin protein family, 
chromogranin (Cg) A and B have been found increased in HF [4-6], and may represent novel 
cardiac biomarkers [4-9]. In addition, chromogranins may affect myocardial function in HF 
[10,11]. For SgII, functional aspects have mainly been attributed to the short 33 amino acid 
peptide secretoneurin (SgII154-186) and a number of interesting pathophysiological effects have 
been reported in other organs than the heart [3]. SgII production is increased by hypoxia in 
skeletal muscle [12], and secretoneurin protects against apoptosis and ischemic injury in the 
brain and skeletal muscle [13,14]. The proteases PC1/3 and PC2 have been identified as the 
principal proteases for processing of SgII to shorter fragments [15,16]. As other granin 
proteins appear to be upregulated during HF development, we hypothesized that SgII 
production is increased in the myocardium and circulation in HF, and that SgII could play a 
role in the pathophysiology of HF following myocardial ischemia. 
  
RESULTS 
Left ventricular SgII gene expression is upregulated during HF development 
To study SgII production in the left ventricle (LV) in HF, we first compared SgII mRNA 
levels in non-infarcted LV tissue of HF animals to levels in sham animals. HF animals 
exhibited increased lung weights and increased LV and right ventricular mass, reflecting 
pulmonary congestion and compensatory myocardial hypertrophy (Supplementary Table 1). 
LV SgII mRNA levels were markedly upregulated in HF animals compared to sham animals 
(11.5 fold increase, p<0.001, Figure 1A). This was a greater relative increase than observed 
for B-type natriuretic peptide (BNP), CgA, or CgB mRNA levels (Supplementary Table 1). 
4

SgII mRNA levels correlated significantly with CgA mRNA levels in HF (r=0.68, p=0.04, 
Figure 1B), but not with CgB or BNP mRNA levels (Supplementary Table 2).  
 
SgII is produced by cardiomyocytes and increase in the LV in HF 
In parallel with observed alterations in SgII mRNA expression, protein levels of SgII were 
significantly increased in both the non-infarcted (35% increase, p=0.02) and the infarcted 
region of the LV (85% increase, p<0.001) in HF animals as measured by radioimmunoassay 
(RIA) (Figure 2A). As previously reported for chromogranins [6,17], SgII immunoreactivity 
in the myocardium was solely confined to cardiomyocytes (Figure 2B). The complex 
processing of SgII (Figure 3A) [3,18] was examined by immunoblotting, and we identified 
increased processing of SgII to shorter SgII fragments in the LV of HF animals compared to 
sham animals (Figure 3B). Finally, levels of the SgII protease PC1/3 were potently increased 
in the non-infarcted and infarcted region of the LV of HF animals (350% increase vs. sham in 
both, p<0.001), while the active form of the SgII protease PC2 (68 kDa) [19] was only 
increased in the infarcted region of HF animals (110% increase, p=0.02) (Figure 3C).  
 
SgII production was not increased in other tissues investigated 
To further study SgII production in HF, we measured SgII protein levels in non-cardiac tissue 
by RIA. As illustrated in Figure 4, SgII levels were not altered in the right ventricle, liver, 
spleen, kidney, stomach, colon, and skeletal muscle during HF development, while SgII levels 
were decreased by 19% (p=0.03) in pulmonary tissue of HF animals. Processing of SgII to 
shorter fragments was not enhanced in HF outside of the LV (Figure 3B). 
 
Transforming growth factor- and norepinehrine increase SgII gene expression in 
cardiomyocytes  
As multiple endocrine and paracrine factors are known to influence cardiomyocyte protein 
synthesis [1], we examined possible factors that could influence SgII production in 
cardiomyocytes. Stimulating neonatal rat cardiomyocytes in vitro for 24 h with transforming 
growth factor- (TGF-) and norepinephrine (NE) increased SgII mRNA levels by 85% 
(p<0.001) and 35% (p=0.02), respectively, while exposure to angiotensin II (AngII), 
endothelin-1 (ET-1), and tumor necrosis factor- (TNF-) did not affect SgII production 
(Figure 5). Forskolin (FSK), which has been shown to induce SgII mRNA expression in other 
cell types [20], was used as a positive control and increased SgII mRNA levels in isolated 
cardiomyocytes by 35% (p=0.001).  
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The SgII fragment secretoneurin reduces ischemia/reperfusion injury in the isolated 
perfused rat heart 
As SgII production was increased in the infarcted LV, we assessed whether the SgII fragment 
secretoneurin could protect against damage after myocardial ischemia. In a global 
ischemia/reperfusion (I/R) model of the isolated perfused rat heart, the addition of 
secretoneurin to the buffer reduced infarct size by 30% (p=0.047) after 30 min of ischemia 
and 2 h of reperfusion (Figure 6A). The beneficial effects of secretoneurin on I/R damage 
were also evidenced by lower LV end-diastolic pressure in the hearts perfused with 
secretoneurin (Figure 6A).  
 
Secretoneurin stimulation increases Stat3 and Erk1/2 phosphorylation and reduces 
hydrogen peroxide-induced apoptosis in isolated cardiomyocytes 
Reduced apoptosis in cardiomyocytes at risk could be a mechanism by which secretoneurin 
protects the myocardium after I/R injury. We therefore investigated whether secretoneurin 
plays a role in the protection of cardiomyocytes exposed to hydrogen peroxide (H2O2). 
Exposure of H2O2 to cardiomyocytes markedly induced apoptosis, as indicated by 
measurements of DNA fragmentation (Figure 6B). We observed that the proportion of 
apoptotic cells after H2O2 exposure was 30% lower (p=0.005) in cells co-stimulated with 
secretoneurin compared to cells in standard medium. Finally, we examined signaling 
pathways that could account for the effects of secretoneurin on I/R injury and cardiomyocyte 
apoptosis. Phospho AktSer473, Erk1/2Thr202/Tyr204, and Stat3Ser727/Tyr705 levels were measured in 
cardiomyocytes after short-term secretoneurin exposure. Secretoneurin stimulation 
significantly increased Erk1/2Thr202/Tyr204 phosphorylation (four and two fold increase after 10 
and 30 min, respectively, p=0.04) (Figure 6C). Stat3Ser727 phosphorylation was increased after 
10 min of secretoneurin exposure (100% increase, p=0.04), while phospho Stat3Tyr705 and 
AktSer473 levels were unaltered.  
 
Circulating levels of SgII are increased in patients with stable HF 
To examine SgII production in patients, we compared plasma levels of SgII in 58 HF patients 
and 20 age- and gender-matched healthy control subjects (Table). In this cohort of stable HF 
patients treated according to updated guidelines, SgII levels were higher than levels in the 
control group: median 0.16 (Q1-3 0.14-0.18) vs. 0.12 (0.10-0.14) nmol/L, p<0.001 (Figure 7). 
Plasma levels of SgII correlated with BNP in HF patients (r=0.26, p=0.05), but not in control 
subjects (r=0.19, p=0.43). SgII levels did not correlate with CgA or CgB levels in control 
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subjects or HF patients (Supplementary Table 3). As evaluated by receiver operating analysis, 
circulating levels of SgII were more closely regulated in HF than both CgA (AUC=0.84 for 
SgII vs. AUC=0.57 for CgA, p=0.001) and CgB levels (AUC=0.68 for CgB, p=0.03 vs. SgII). 
Use of a proton pump inhibitor (PPI), a medication known to increase circulating CgA levels 
[6], did not increase SgII levels as levels in patients using PPI (n=8) were similar to SgII 
levels in the other HF patients: 0.16 (Q1-3 0.13-0.19) vs. 0.16 (0.14-0.18) nmol/L, 
respectively, p=0.68).   
 
DISCUSSION 
In the present study we demonstrate for the first time that the expression of SgII, a member of 
the granin protein family, is increased in the LV during HF development. Moreover, SgII 
processing to shorter fragments is increased in the LV in post-infarction HF, which could be 
beneficial as the SgII fragment secretoneurin protects against myocardial I/R injury and 
cardiomyocyte apoptosis. SgII production was not increased in other tissues investigated, and 
therefore the LV could be a significant contributor to the elevated circulating SgII levels in 
patients with HF.  
 
Myocardial production of SgII in HF 
HF is associated with increased myocardial production of several protein families [1,2]. Like 
other granin proteins, SgII is a pro-hormone with multiple dibasic cleavage sites [3]. Although 
the processing of SgII is known to be more complex than for most other pro-hormones [3,21], 
SgII has in several tissues been demonstrated to be almost fully processed to the short 33 
amino acid peptide secretoneurin [22]. In the circulation, the majority of SgII 
immunoractivity is also reportedly found in the form of secretoneurin [22]. Pertinent to this, 
data from non-cardiac tissue have indicated that cells with an enhanced secretory rate exhibit 
increased processing of SgII to shorter fragments [18]. Accordingly, our novel data 
demonstrating increased levels and processing of SgII to shorter fragments in the LV during 
post-myocardial infarction HF point to the myocardium as a significant contributor to the 
increased circulating levels of SgII in HF. This is supported by the lack of increase in SgII 
production in non-cardiac tissue in HF. The mechanism by which SgII processing is increased 
seems to be enhanced PC1/3 (previously denoted PC1 or PC3) and PC2 activity in the LV, 
which are the principal proteases of SgII [15,16]. The complex processing of SgII in the LV 
with several shorter fragments corresponds to immunoblots of SgII processing in non-cardiac 
tissue [15,16,18,21,22]. One report has previously demonstrated increased PC1/3 mRNA 
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levels close to the infarct area in rats with myocardial infarction and HF [23], but to our 
knowledge the increase in both PC1/3 and PC2 in the LV of animals with HF has previously 
not been reported. Increased PC1/3 and PC2 activity has been hypothesized as a conceptual 
model for enhanced SgII processing in non-cardiac cells [18].    
 
We identified cardiomyocytes as the cell type responsible for SgII production in the 
myocardium. This is in line with previous data for chromogranins [6,17], and with a report 
published during progression of our work that demonstrates the presence of SgII in the 
healthy rodent myocardium [24]. We have also previously demonstrated that NE, TGF-, and 
AngII regulate CgB production in cardiomyocytes [6]. Similar to this, we now report that 
TGF- and NE both induce SgII mRNA expression in cardiomyocytes in vitro, while AngII 
failed to increase SgII mRNA levels. Distinct regulation of different granins has been reported 
in other cell types and may be explained by variations in the promoter region, including the 
serum response element (SRE), which is only found in the SgII promoter [20]. Effect of 
growth factors on SRE promoter sites could explain the potency of TGF- as a stimulus for 
SgII production in cardiomyocytes [20], but the precise mechanism regulating cardiomyocyte 
SgII production needs to be established in future studies. This also relates to a possible role of 
hypoxia-inducible factor-1 (HIF-1) as a regulator of SgII production after myocardial 
ischemia. Indeed, HIF-1 has previously been found to increase SgII production in skeletal 
muscle subjected to hypoxia [12], and we found SgII production increased in the LV of 
animals with myocardial infarction and HF.  
Functional aspects of the SgII fragment secretoneurin in the myocardium 
Proteins produced by the heart during the development of HF may exert their actions via 
endocrine, paracrine or autocrine mechanisms [1]. Findings in the current study suggest that 
SgII and the fragment secretoneurin could exert important effects in the myocardium by 
reducing I/R injury and cardiomyocyte apoptosis. These effects of secretoneurin, together 
with the observation that LV SgII levels and processing are increased in animals with 
myocardial infarction and HF, are compatible with known functional properties of 
secretoneurin. Secretoneurin has previously been found to attract leukocytes, especially 
monocytes [25], and may be of importance for the early post-infarction inflammatory 
response in the myocardium. Secretoneurin also attracts endothelial cells, both mature 
endothelial cells for angiogenesis [26] and bone marrow-derived progenitor endothelial cells 
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for vasculogenesis [27], suggesting that secretoneurin could play a role in revascularization of 
infarcted myocardial tissue.  
 
In this study, we have shown for the first time that secretoneurin attenuates cardiomyocyte 
apoptosis and reduces infarct size in the subacute phase after myocardial infarction. A 
putative mechanism for this effect of secretoneurin against I/R injury, is via reduction of 
cardiomyocyte apoptosis in the border zone, possibly mediated by Erk1/2 and Stat3 activation 
[28,29]. Other studies have shown that secretoneurin protects endothelial cells from apoptosis 
through Erk1/2 signaling [26,27], and attenuates neuronal cell death after ischemia by 
induction of the Jak/Stat pathway [13], providing support for secretoneurin as a protective 
factor in the subacute phase of tissue ischemia. However, we have not assessed the long-term 
effects of increased SgII levels for organ function in HF and this should be explored in future 
studies. Before the long-term effects of secretoneurin have been established, the net effect by 
increased SgII levels in HF cannot be estimated, although we provide evidence that LV SgII 
production seems to be protective in the subacute phase of post-infarction HF development.  
Circulating SgII levels  in patients with HF  
In this first report on SgII in HF, we find circulating SgII levels to be increased in stable 
patients with mainly moderate severity of HF compared to age- and gender-matched control 
subjects. We also find SgII levels to be more closely increased in our patients with stable HF 
compared to CgA and CgB levels, but whether SgII have additional diagnostic and prognostic 
utility over other granin biomarkers in HF will need to be explored in future studies.  
Conclusion
We have observed increased myocardial SgII production and processing to shorter fragments 
in animals with myocardial infarction and HF. This could be beneficial as the SgII fragment 
secretoneurin protects from I/R injury and cardiomyocyte apoptosis. As SgII production was 
not enhanced in other tissues investigated, LV SgII production could be a significant 
contributor to the elevated circulating levels of SgII in patients with HF.  
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METHODS 
Animal experiments were performed according to recommendations from the European 
Council for Laboratory Animal Science and approved by the Norwegian Council for Animal 
Research (#HR0506). The study protocol of the clinical study was approved by the South-
Eastern Regional Ethics Committee Norway (#1.2006.2653) before the initiation of the study, 
and all participants gave their written informed consent prior to study commencement. 
 
Mouse model of HF 
Mice were anesthetized with 0.2 mg propofol in the tail vein, trachetomized, connected to an 
animal ventilator, and ventilated with a mixture of 98% oxygen and 2% isoflurane during 
surgery. A permanent ligation of the left main coronary artery was performed in mice and the 
animals were evaluated by echocardiography for development of HF [30]. Sham-operated 
(sham) animals underwent the same procedure without coronary artery ligation. All efforts 
were made to minimize suffering. Animals were sacrificed at one week post-surgery, when 
hearts and other organs were dissected, prepared, and stored as previously described [6].   
 
RT-qPCR, radioimmunoassays, immunhistochemistry, and immunoblotting 
mRNA levels were measured with TaqMan Gene Expression assays from Applied Biosystems 
(Foster City, CA, USA): (i) mouse myocardium: SgII (Mm00843883_s1), CgA 
(Mm00514341_m1), CgB (Mm00483287_m1), BNP (Mm00435304_g1), ribosomal protein 
L4 (RPL4) (Mm00834993_g1); and (ii) neonatal rat cardiomyocytes: SgII (Rn01400686_g1) 
and RPL4 (Rn00821091_g1). SgII protein levels in tissue and plasma were measured by a 
RIA binding to the secretoneurin region of SgII (SgII154-165) [31]. The detection limit of the 
SgII RIA in plasma is 0.05 nmol/L and the assay has a coefficient of variation (CV) of 9% in 
the lower range (1.10 nmol/L) and 4% in the upper range (3.80 nmol/L). We used a 
commercial RIA for CgA analysis (EuroDiagnostica AB, Malmö, Sweden) with a detection 
limit of 0.8 nmol/L and a CV of 13% in the lower range (3.1 nmol/L) and 9% in the upper 
range (17.0 nmol/L), while an in-house RIA was used for CgB analysis with detection limit 
0.80 nmol/L and a CV of 17% in the lower range (1.40 nmol/L) and 8% in the upper range 
(6.40 nmol/L) [32]. For immunoblotting we used an N-terminal SgII antibody (ab20246, 
Abcam, Cambridge, UK) as SgII processing has been reported to start from the C-terminal 
end [18]. We quantitated three bands of SgII (81, 66, and 55 kDa) according to previous data 
on SgII processing in non-cardiac tissue [18]. Additional antibodies for immunoblotting and 
immunhistochemistry are reported in the Data Supplement.    
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Regulation of SgII mRNA production in neonatal rat cardiomyocytes 
After 24 h starvation of the cells, neonatal rat cardiomyocytes were stimulated as previously 
reported [6] for 24 h with the following agents; forskolin (FSK) [10 μM], norepinephrine 
(NE) [100 μM], endothelin-1 (ET-1) [250 ng/mL], angiotensin II (AngII) [1 μM] (all Sigma-
Aldrich, St. Louis, MO, USA), tumor necrosis factor- (TNF-) [10 ng/mL] (BioSource 
International, Camarillo, CA, USA), and transforming growth factor- (TGF-) [10 ng/mL] 
(R&D Systems, Minneapolis, MN, USA).  
 
Langendorff perfusion 
All rats were anesthetized with 5% sodium pentobarbital (60-80 mg/kg intraperitoneally (i.p)) 
and heparinised (500 IU i.p). After anesthesia, rat hearts were rapidly excised and placed in 
ice-cold Krebs-Henseleit Buffer (KHB) (mmol/L: NaCl 118.5; NaHCO3 25; KCl 4.7; KH2PO4 
1.2; MgSO4/7H2O 1.2; glucose/1H2O 11.1; CaCl2 1.8) for further dissection. After aortic 
cannulation, the hearts were mounted on a Langendorff system (AD Instruments Pty Ltd, 
Castle Hill, NSW 2154, Australia) and retrogradely perfused with warm (37ºC), oxygenated 
(95% O2, 5% CO2) KHB at constant pressure of 70 mmHg. After 40 min of stabilization, 
hearts were subjected to 30 min of global ischemia, and then reperfused for 120 min 
(Supplementary Figure). In the experimental group (secretoneurin group), 0.66 μg/mL 
secretoneurin (NeoMPS, Strasbourg, France) was added to the perfusate 20 min prior to 
ischemia, and was also used throughout the reperfusion period. A recirculation system was 
inserted from 20 min prior to induction of ischemia in both groups (Supplementary Figure), 
and used throughout the reperfusion period. Infarct size was calculated with Adobe Photoshop 
(Adobe Systems, San Jose, CA, USA) as percentage of the total area by an investigator 
blinded to treatment. 
 
Effect of secretoneurin on phospho proteins 
To assess the short-term effect of secretoneurin stimulation on phospho proteins, the 
cardiomyocytes were stimulated for 10 or 30 min with 10 μg/mL secretoneurin (NeoMPS) or 
vehicle. Cells were harvested in lysis buffer (Tris pH 7.6, 5M NaCl, 0.5M EDTA, 0.1M 
EGTA, 1M B-gly [Sigma-Aldrich St. Louis, MO, USA] and NP-40), and the protein levels 
measured by immunoblotting (details reported in the Data Supplement). 
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Cell Death Enzyme-linked Immunosorbent Assay
Neonatal rat cardiomyocytes were stimulated with 10 μg/mL secretoneurin (NeoMPS) or 
vehicle for 24 h, followed by 24 h exposure to hydrogen peroxide (H2O2, 100 mol) in the 
presence of secretoneurin or vehicle. Cells were then harvested in lysis buffer and apoptosis 
assessed using the Cell Death Enzyme-linked Immunosorbent Assay (Cell Death Detection 
ELISAPLUS, Roche, Basel, Switzerland) according to manufacturer procedure. 
 
Patients with stable HF and control subjects 
Fifty-eight patients with echocardiographically documented impaired systolic function [LV 
ejection fraction (LVEF) 50%], and no hospitalization for HF during the last three months 
prior to study commencement, were compared to 20 control subjects with no history or 
current symptoms of chronic disease. The control subjects had a normal physical examination, 
did not use medication regularly, and were hospital employees or recruited from outside of the 
hospital. 
 
 Statistical analysis 
Continuous data are presented as mean (± SEM) or median (quartile [Q] 1-3) and categorical 
values as counts (percentage). Continuous variables were compared by Student's t-test except 
circulating biomarker values that were compared by the Mann-Whitney U-test due to a right-
skewed distribution. Serial data were compared by Two-Way ANOVA, and categorical data 
by the chi-square test or Fisher's exact test as appropriate. Correlations were calculated by 
Spearman rank correlation. P-values <0.05 were considered significant for all analyses. 
Statistical analyses were performed with SPSS for Windows version 16.0 (SPSS, Chicago, 
IL) except receiver operating analysis which was performed with MedCalc for Windows, 
version 9.5.1.0 (MedCalc Software, Mariakerke, Belgium) by the method of Hanley and 
McNeil [33].  
 
Details regarding methods can be found in the Data Supplement.  
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FIGURE LEGENDS 
Figure 1. Left ventricular SgII gene expression in heart failure. A, SgII mRNA levels in 
non-infarcted left ventricular tissue during HF development. SgII mRNA levels were 11.5 
fold increased (p<0.001) in non-infarcted LV tissue in HF animals (n=9) compared to sham-
operated animals (n=8). Gene expression was measured by RT-qPCR and is presented as fold 
change ± SEM. B, LV SgII mRNA levels were closely correlated with CgA mRNA levels in 
both HF (r=0.68, p=0.04) and sham animals (r=0.81, p=0.02).  
 p<0.001  
 
Figure 2. SgII is produced by cardiomyocytes and increased in the left ventricle during 
HF development. A, SgII protein levels as measured by RIA were increased in both the non-
infarcted and infarcted region of the LV in HF animals compared to levels in the myocardium 
of sham-operated animals (n=9 for both groups). B, Representative photomicrographs of 
myocardial tissue sections of a HF mouse demonstrating SgII immunoreactivity (brown 
staining) in cardiomyocytes bordering the infarcted zone (border zone, lower left), in the 
remote non-infarcted myocardium (upper left), and in surviving cardiomyocytes of the 
infarcted region (upper right). Bottom right picture demonstrates very weak staining after use 
of non-immune rabbit serum as control (ctr). Magnification: ×200. 
 p<0.001,  p<0.01. 
 
Figure 3. SgII processing is increased in the left ventricle of HF mice. A, Figure of SgII 
processing as reported in non-cardiac tissue (modified from ref. 18). B, SgII processing in the 
left and right ventricles in HF and sham animals. Bands at 81 kDa, 66 kDa, and 55 kDa were 
measured and are presented as fold change (SEM) vs. sham animals (n=6 for each group). C, 
Levels of the proteases PC1/3 and PC2 in the left and right ventricles in HF and sham 
animals.   
 
Figure 4. SgII production outside of the left ventricle in heart failure. SgII levels were 
decreased in pulmonary tissue during HF development, while levels were unchanged in the 
other tissues examined. SgII levels in the (A) right ventricle, (B) pulmonary tissue, (C) liver, 
(D) spleen, (E) kidney, (F) stomach, (G) colon, and (H) skeletal muscle were measured by 
RIA and are presented as fold change ± SEM (n=6 for both groups, except pulmonary tissue: 
HF: n=14, sham: n=13).  
# p<0.05. 
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Figure 5. Regulation of cardiomyocyte SgII expression by important hormonal and 
paracrine factors in HF. SgII mRNA levels were measured by RT-qPCR after stimulating 
neonatal rat cardiomyocytes for 24 h with either PBS (Ctr, n=9), forskolin (FSK n=5), 
norepinephrine (NE, n=5), angiotensin II (AngII, n=4), endothelin-1 (ET-1, n=5), 
transforming growth factor- (TGF-, n=6), or tumor necrosis factor- (TNF-, n=6). SgII 
mRNA levels are presented as fold change ± SEM vs. PBS-stimulated cells.  
 p<0.001,  p<0.01, # p<0.05. 
 
Figure 6. The secretogranin II fragment secretoneurin has protective effects during 
myocardial ischemia and cardiomyocyte stress. A, Secretoneurin reduces infarct size by 
30% (upper left) and improves myocardial function (upper right) after global ischemia in the 
isolated perfused rat heart. B, Cardiomyocyte apoptosis in vitro after H2O2 exposure was 
attenuated by secretoneurin stimulation. Cells were extracted from 5 different cell isolations 
(n=5 for all groups). C, Short-term stimulation of cardiomyocytes with 10 μg/mL 
secretoneurin (SN) activated protective intracellular pathways as reflected by increased Stat3 
and Erk1/2 phosphorylation (n=5 for all groups).  
 p<0.001,  p<0.01, # p<0.05.   
 
Figure 7. Circulating SgII levels are elevated in patients with chronic, stable HF. SgII 
levels were significantly increased in HF patients (n=58) compared to healthy age- and 
gender-matched control subjects (n=20): Median 0.16 (Q1-3 0.14-0.18) vs. 0.12 (0.10-0.14) 
nmol/L, p<0.001. HF patients are presented according to NYHA functional class. The 
horizontal line within the box represents the median level, the boundaries of the box the 25th 
and 75th percentile levels, and the whiskers the 10th-90th percentile.  
 p<0.001 
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Table. Descriptive statistics of heart failure patients and control subjects 
 Control subjects 
(n=20) 
HF patients 
(n=58) 
 p 
Male sex (n, %) 16 (80%) 47 (81%)  0.92 
Age, years (mean ± SEM) 60.6 ± 1.1 62.8 ± 1.6  0.43 
NYHA class (n, %)     
II  47 (81%)   
III  11 (19%)   
Etiology for HF (n, %) 
Ischemic 
Dilated cardiomyopathy 
Other 
  
35 (60%) 
21 (36%) 
2 (4%) 
  
Duration of HF, months (median, Q1-3)  18 (12-48)   
LVEF, % (mean ± SEM)  33 ± 1   
Medication (n, %) 
-blocker
ACEI
ARB
ACEI or ARB
Aldosterone antagonist
Diuretic
Statin
Warfarin
ASA
Clopidogrel
Digitalis
Amiodarone
Nitrate
PPI
  
57 (98%) 
41 (71%) 
17 (29%) 
58 (100%) 
11 (19%) 
43 (74%) 
38 (65%) 
29 (50%) 
34 (59%) 
7 (12%) 
14 (24%) 
6 (10%) 
6 (10%) 
8 (14%) 
  
CRT  10 (17%)   
ICD  11 (19%)   
CgA levels, nmol/L  4.5 (4.0-5.3) 5.0 (3.5-8.2)  0.33 
CgB levels, nmol/L  1.47 (1.39-1.58) 1.63 (1.44-1.80)  0.02 
20

BNP levels, pg/mL  26 (13-37) 197 (89-338)  <0.001 
 
NYHA class indicates New York Heart Association functional class; Q1-3, quartile 1-3; 
LVEF, left ventricular ejection fraction; ACEI, angiotensin converting enzyme inhibitor; 
ARB, angiotensin II receptor blocker; ASA, acetyl salicylic acid; PPI, proton pump inhibitor; 
CRT, cardiac resynchronization therapy; ICD, implantable cardioverter-defibrillator; CgA, 
chromogranin A; CgB, chromogranin B; and BNP, B-type natriuretic peptide. Biomarker 
levels are presented as median (quartile 1-3). 
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SUPPLEMENTAL METHODS 
Mouse model of HF 
Six week old C56BL/6 mice (Taconic, Skensved, Denmark) were used for experiments. 
Surgical procedures were performed as earlier described with a permanent ligation of the left 
main coronary artery in the heart failure (HF) group after a left-sided thoracotomy and 
pericardectomy [1]. Sham-operated animals (sham) were subjected to the same procedure 
except ligation of the coronary artery. A full echocardiographic examination was performed 
one week after the primary operation while animals were anesthetized breathing a gas mixture 
of oxygen and isoflurane supplied via a facemask. Inclusion in the HF group was based on 
criteria previously validated by our group as sensitive and specific for diagnosing HF: 1) 
Myocardial infarction >40 % of the circumference of the left ventricle (LV), 2) left atrial 
diameter >2.0 mm, 3) >35 % increase in lung weight compared to the sham group (e.g. lung 
weight >0.2 g) [2].  
 
After sacrificing the animals, hearts and the other organs were dissected, prepared, and stored 
as previously described [1]. In the LV, the thin infarcted region was dissected from the 
hypertrophic non-infarcted region. To avoid interference of necrotic cardiomyocytes to non-
infarcted LV tissue, the transformation zone (border zone) was included in the infarcted 
region. Tissue for RT-qPCR analysis or immunoblotting were immediately frozen in liquid 
nitrogen and stored at 70°C until use. 
 
Quantitative real-time PCR (RT-qPCR)  
RNA was extracted from the non-infarcted region of mice LV tissues using the SV Total 
RNA Isolation System (Promega Corporation, Madison, WI, USA) as previously described 
(20-35 mg, 9 HF mice and 8 sham) [1]. From neonatal rat cardiomyocytes, total RNA was 
isolated with the RNeasy mini kit (Qiagen, Hilden, Germany), RNA concentration and quality 
was assessed [1], and cDNA produced with the High-Capacity cDNA Archive kit (Applied 
Biosystems, Foster City, CA, USA) or the iScript cDNA Synthesis Kit (Bio-Rad Laboratories 
Inc., Hercules, CA, USA). The results were detected on a 7900 HT Real-Time PCR System 
(Applied Biosystems), and the relative gene expression was determined by the standard curve 
method [3]. All samples were run in triplicate, RPL4 served as an internal control, and levels 
are presented as fold change (change from the mean in the sham group) ± SEM. 
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Radioimmunoassay on tissue homogenate 
Frozen myocardial tissue samples were homogenized and pre-treated with SDS, and the total 
protein content measured as previously described [1]. SgII levels were measured by an in-
house made region-specific radioimmunoassay (RIA) detecting the secretonurin part of SgII 
(SgII154-165) [4]. No sample had SgII levels below the detection limit (<1 fmol/tube). All 
samples were measured in duplicate.  
 
1-D gel electrophoresis and immunoblotting 
We performed 1-D gel electrophoresis and immunoblotting according to standard procedures. 
Total protein content was measured with the micro BCA protein assay kit (Pierce 
Biotechnology, Rockford, IL, USA), and the lysates were denaturated for 5 min at 100°C 
prior to gel loading [1]. We used polyacrylamide gels (10-12 %) and the Precision Plus 
Protein Dual Color Standard (161-0374) as the molecular marker (Bio-Rad Laboratories Inc.). 
A Mini Trans-Blot Cell system (Bio-Rad Laboratories Inc.) was used to transfer proteins from 
gels to Hybond-P PVDF membranes (RPN303F, Amersham Biosciences Europe, Freiburg, 
Germany). Non-specific binding to the membrane was blocked with 5% dry milk in TBS/1% 
Tween for 2 h. After an overnight incubation with the primary monoclonal mouse anti-SgII 
antibody (diluted 1:5000, ab20246, Abcam, Cambridge, UK) at 4°C, the membranes were 
incubated for 1 h with a secondary goat anti-mouse IgG antibody (1030-50, Southern Biotech, 
Birmingham, AL, USA). Membranes were washed in between and after all incubation steps 
with TBS/1% Tween. The primary polyclonal anti-PC1/3 antibody was from Millipore, 
Billerica, MA, USA (diluted 1:500, AB10553) and the primary polyclonal anti-PC2 antibody 
was from Santa Cruz Biotechnology, Santa Cruz, CA, USA (diluted 1:100, sc-22891). The 
secondary antibody for PC1/3 was goat anti-rabbit IgG antibody (4030-05, Southern Biotech) 
and for PC2 a rabbit anti-goat IgG antibody (6160-05, Southern Biotech). The band at 110 
kDa was measured for PC1/3 according to the manufacturer’s specifications [5], while the 
bands at 75 and 68 kDa were assessed to determine the pro-form and active form of PC2, 
respectively [6]. 
 
We used a similar protocol to assess Stat3, Akt, and Erk1/2 regulation in cardiomyocytes after 
secretoneurin stimulation. Membranes were first incubated with phosphospesific antibodies 
against Stat3 (Tyr705 or Ser724), Akt (Ser473), and Erk1/2 (Thr202/Tyr204), then stripped, before 
being reprobed with antibodies against total Stat3, Akt and Erk1/2 for equal protein loading 
(all antibodies from Cell Signaling Technologies, Beverly, MA, USA). Levels of 
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phosphorylated protein forms were normalized to the corresponding total level of Stat3, Akt 
or Erk1/2.  
 
Immunohistochemistry  
The distribution of SgII in the myocardium was examined in 3 mice with HF. Hearts were 
removed, fixed overnight in 4% formalin, washed in 30% ethanol and stored in 70% ethanol 
at 4°C before use. We used a SgII antibody binding to the C-terminal region of secretoneurin 
(SgII172-186) [7] that were followed by anti-goat IgG (Vector Laboratories, Burlingame, CA, 
USA). The avidin-biotin-peroxidase system (Vectastain Elite kit, Vector Laboratories) was 
used to further amplify immunoreactivity, before sections were counter-stained with 
hematoxylin [1]. To investigate unspecific staining, we used non-immune rabbit serum or 
omitted the primary antibody.   
 
Langendorff perfusion 
Male Wistar rats (250-350 g, Scanbur AS, Nittedal, Norway) were used for these experiments. 
Animals were acclimatized for at least four days before any experiments were conducted.  
The heart temperature was kept constant during the experiment by the surrounding glass tube 
(inner diameter 40 mm, height 80 mm) perfused with water from the heating chamber. A 
fluid-filled latex balloon was inserted into the LV to measure ventricular pressures by a 
Powerlab system (AD Instruments Pty Ltd, Castle Hill, NSW 2154, Australia). LV end-
diastolic pressure (LVEDP) was set to 5-10 mmHg and changes in LVEDP were measured. 
Myocardial temperature was controlled by inserting a temperature probe in the right ventricle. 
The hearts with LV systolic pressure  100 mmHg, coronary flow  8 or  20 mL/min, heart 
rate  220 beats per minute before ischemia, or irreversible arrhythmias for more than 30 min 
during reperfusion were excluded from the study. After 120 min of reperfusion, the hearts 
were cut in four slices of 1 mm and three slices of 2 mm (hearts fixed in acrylic rat brain 
matrix by AgnThor´s AB, Lidingö, Sweden). The 2 mm slices were freeze clamped in liquid 
nitrogen and stored for later analyses, while the other slices collected 5-8 mm from apex were 
incubated in 1% triphenyltetrazoliumchloride for 15 min at 37ºC. After incubation the slices 
were gently pressed between two glass plates and photographed (Nikon, Colorfix5400, 
Tokyo, Japan).  
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Cell culture experiments  
Neonatal (1-3 days) Wistar rats (Taconic) were used for extraction of cardiomyocytes as 
previously reported [8]. Total RNA was isolated, quality assessed, and mRNA levels 
determined as described above. To assess the short-term effect of secretoneurin stimulation on 
phospho proteins, the cardiomyocytes were stimulated for 10 or 30 min with 10 μg/mL 
secretoneurin (NeoMPS, Strasbourg, France) or vehicle. Cells were harvested in lysis buffer 
(Tris pH 7.6, 5M NaCl, 0.5M EDTA, 0.1M EGTA, 1M B-gly [Sigma-Aldrich St. Louis, MO, 
USA] and NP-40), and the protein levels measured by Western blotting as described above.  
 
Patients with HF and healthy control subjects 
Inclusion of HF patients and healthy control subjects were performed as previously described 
[1]. For this study we only included stable HF patients, e.g. patients not hospitalized for 
worsening of HF during the last three months prior to study commencement. A transthoracic 
echocardiogram had been obtained within the last 18 months in 55 of the 58 patients (95%). 
The last 3 patients had been clinically stable during this period as evaluated by no change in 
severity of HF symptoms or New York Heart Association (NYHA) functional class in the last 
12 months, and no hospitalization for worsening HF in the last 24 months. One of these 
patients had a LV ejection fraction of 20% and no evidence of reversible myocardial ischemia 
when evaluated by myocardial single photon emission computed tomography (SPECT) during 
the last year prior to study inclusion. Fifty-four patients (93%) had undergone coronary 
angiography for diagnostic purposes. New York Heart Association (NYHA) functional class 
were determined by one investigator (HR). All patients were included from Akershus 
University Hospital's HF outpatient clinic.  
 
Blood samples were processed as previously described [1], and plasma B-type natriuretic 
peptide (BNP) levels measured by a two-step sandwich immunoassay (Architect® BNP assay, 
Abbott Diagnostics, Abbott Park, IL, USA). Plasma CgA levels were measured by a 
commercial RIA identifying CgA116-439 (Euro-Diagnostica AB, Malmö, Sweden) and CgB 
levels assessed by a region-specific RIA detecting CgB439-451 [9].  
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Supplementary Table S1. Descriptive statistics of animals 
  Sham 
(n=21) 
HF 
(n=27) 
p 
Animal weight, day 0 (g) 24.4 ± 0.4 24.4 ± 0.4 0.95 
Lung weight/tibial length (g/mm) 0.079 ± 0.001 0.156 ± 0.007 <0.001 
LV mass/tibial length (g/mm) 0.045 ± 0.001 0.058 ± 0.001 <0.001 
RV mass/tibial length (g/mm) 0.011 ± 0.001 0.013 ± 0.001 0.01 
LV CgA mRNA levels  1.0 ± 0.4 4.8 ± 1.4 0.02 
LV CgB mRNA levels 1.0 ± 0.1 5.2 ± 0.7 <0.001 
LV BNP mRNA levels 1.0 ± 0.1 5.8 ± 0.7 <0.001 
 
LV indicates left ventricle; RV, right ventricle; CgA, chromogranin A; CgB, chromogranin B; 
and BNP, B-type natriuretic peptide. mRNA levels were investigated in a subset of animals 
(n=9 HF, n=8 sham) and are presented as fold change ± SEM.  
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Supplementary Table S2. Correlations between mRNA levels of granins and BNP in the 
left ventricle of heart failure and sham-operated mice 
 
 SgII mRNA levels 
 Sham animals HF animals 
CgA mRNA levels r= 0.81, p= 0.02 r= 0.68, p= 0.04 
CgB mRNA levels r= 0.10, p= 0.82 r= 0.18, p= 0.64 
BNP mRNA levels r= -0.02, p= 0.96 r= 0.38, p= 0.31 

 
 
 
 
 
 
 
Supplementary Table S3. Correlations between circulating levels of granin proteins and 
BNP in patients with heart failure and healthy control subjects 
 
 SgII levels 
 Control subjects HF patients 
CgA levels r= -0.26, p= 0.27 r= 0.16, p= 0.25 
CgB levels r= -0.34, p= 0.14 r= 0.09, p= 0.49 
BNP levels r= 0.19, p= 0.43 r= 0.26, p= 0.05 
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Supplementary Figure. Langendorff perfusion. Hearts from male adult rats were rapidly 
excised and mounted on a Langendorff system. After 40 min of stabilization, hearts were 
subjected to 30 min of global ischemia, and then reperfused for 120 min. In the experimental 
group (secretoneurin group), 0.66 μg/mL secretoneurin (SN) was added to the perfusate 20 
min prior to ischemia, and also used throughout the reperfusion period. 
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